<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001304" GROUP_ID="CF" ID="143499080510024974" MERGED_FROM="" MODIFIED="2009-11-03 14:57:50 +0100" MODIFIED_BY="Nikki Jahnke" REVIEW_NO="0015" REVMAN_SUB_VERSION="5.0.22" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2009-11-03 14:57:50 +0100" MODIFIED_BY="Nikki Jahnke">
<TITLE>Dietary interventions for phenylketonuria</TITLE>
<CONTACT MODIFIED="2009-11-03 14:57:50 +0100" MODIFIED_BY="Nikki Jahnke"><PERSON ID="12982" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Vanessa</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Poustie</LAST_NAME><POSITION>Associate Director, UK Medicines for Children Research Network</POSITION><EMAIL_1>v.poustie@liv.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Institute of Child Health, University of Liverpool</DEPARTMENT><ORGANISATION>Alder Hey Children's NHS Foundation Trust</ORGANISATION><ADDRESS_1>Eaton Road</ADDRESS_1><CITY>Liverpool</CITY><ZIP>L12 2AP</ZIP><REGION>Merseyside</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+ 44 151 252 5439</PHONE_1><FAX_1>+ 44 151 252 5456</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-11-03 14:57:50 +0100" MODIFIED_BY="Nikki Jahnke"><PERSON ID="12982" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Vanessa</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Poustie</LAST_NAME><POSITION>Associate Director, UK Medicines for Children Research Network</POSITION><EMAIL_1>v.poustie@liv.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Institute of Child Health, University of Liverpool</DEPARTMENT><ORGANISATION>Alder Hey Children's NHS Foundation Trust</ORGANISATION><ADDRESS_1>Eaton Road</ADDRESS_1><CITY>Liverpool</CITY><ZIP>L12 2AP</ZIP><REGION>Merseyside</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+ 44 151 252 5439</PHONE_1><FAX_1>+ 44 151 252 5456</FAX_1></ADDRESS></PERSON><PERSON ID="C20E11F182E26AA2005DA3647622D42A" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Joanne</FIRST_NAME><LAST_NAME>Wildgoose</LAST_NAME><POSITION>Paediatric Dietitian</POSITION><EMAIL_1>Jo.Wildgoose@bradfordhospitals.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Physio Corridor, Level 1</DEPARTMENT><ORGANISATION>Bradford Royal Infirmary</ORGANISATION><ADDRESS_1>Duckworth Lane</ADDRESS_1><CITY>Bradford</CITY><ZIP>BD9 6RJ</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-09-21 09:31:45 +0100" MODIFIED_BY="Nikki Jahnke">
<UP_TO_DATE>
<DATE DAY="21" MONTH="9" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="5" MONTH="3" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="3" MONTH="10" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="1999"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="1999"/>
</DATES>
<WHATS_NEW MODIFIED="2009-11-03 13:48:47 +0000" MODIFIED_BY="Nikki Jahnke">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-11-03 13:48:37 +0000" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="21" MONTH="9" YEAR="2009"/>
<DESCRIPTION>
<P>A search of the Group's Inborn Errors of Metabolism Trials Register identified nine new references. One reference was an additional reference to a previously excluded study (<LINK REF="STD-Robertson-2004" TYPE="STUDY">Robertson 2004</LINK>). Eight references were excluded (<LINK REF="STD-Cleary-2006" TYPE="STUDY">Cleary 2006</LINK>; <LINK REF="STD-Kakanoglu-2005" TYPE="STUDY">Kakanoglu 2005</LINK>; <LINK REF="STD-Koletzko-2007" TYPE="STUDY">Koletzko 2007</LINK>; <LINK REF="STD-Levy-2007" TYPE="STUDY">Levy 2007</LINK>; <LINK REF="STD-Lou-1987" TYPE="STUDY">Lou 1987</LINK>; <LINK REF="STD-Pietz-1995" TYPE="STUDY">Pietz 1995</LINK>; <LINK REF="STD-Schindeler-2007" TYPE="STUDY">Schindeler 2007</LINK>; <LINK REF="STD-Smith-1998" TYPE="STUDY">Smith 1998</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-11-03 13:48:43 +0000" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="21" MONTH="9" YEAR="2009"/>
<DESCRIPTION>
<P>The Plain Language Summary has been updated in light of current guidance from The Cochrane Collaboration.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2009-11-03 13:48:47 +0000" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="21" MONTH="9" YEAR="2009"/>
<DESCRIPTION>
<P>Mrs Patricia Rutherford has stepped down as author from this update of the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-08-10 09:30:09 +0100" MODIFIED_BY="Nikki Jahnke">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-08-10 09:30:09 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="6" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-11-06 11:00:34 +0000" MODIFIED_BY="Tracey Remmington">
<DATE DAY="5" MONTH="5" YEAR="2007"/>
<DESCRIPTION>
<P>A new search of the Group's Inborn Errors of Metabolism Trials Register identified six references which were found not to be eligible for inclusion in the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-11-06 10:58:51 +0000" MODIFIED_BY="Tracey Remmington">
<DATE DAY="31" MONTH="3" YEAR="2006"/>
<DESCRIPTION>
<P>A new search of the group's register identified two references to one study which has been listed under <LINK TAG="EXCLUDED_STUDIES" TYPE="SECTION">Excluded studies</LINK> (<LINK REF="STD-Robertson-2004" TYPE="STUDY">Robertson 2004</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-11-06 10:59:23 +0000" MODIFIED_BY="Tracey Remmington">
<DATE DAY="5" MONTH="4" YEAR="2004"/>
<DESCRIPTION>
<P>The search for trials identified one further reference to the already included US/PKU Collaborative 1997 trial. This reference contained no further data for inclusion in the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-11-06 11:00:02 +0000" MODIFIED_BY="Tracey Remmington">
<DATE DAY="6" MONTH="2" YEAR="2003"/>
<DESCRIPTION>
<P>Two further publications containing data from one of the included studies (US/PKU Collaborative) have been identified. Only data relating to phenylalanine intake could be extracted from these for inclusion in the review. The inclusion of these data does not affect the overall results of this review.<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>North West NHS Executive Research &amp; Development Directorate Training Fellowship Scheme</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>British Dietetic Association General Education Trust</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-10-28 16:50:46 +0000" MODIFIED_BY="Nikki Jahnke">
<SUMMARY MODIFIED="2009-08-06 10:12:03 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-08-06 10:11:53 +0100" MODIFIED_BY="[Empty name]">Using diet to manage phenylketonuria</TITLE>
<SUMMARY_BODY MODIFIED="2009-08-06 10:12:03 +0100" MODIFIED_BY="[Empty name]">
<P>Phenylketonuria (PKU) is an inherited disease that affects the breakdown of protein. High levels of the amino acid phenylalanine in the blood damage the nervous system and can also lead to mental handicap. Newborn babies with PKU are given a special diet low in phenylalanine. Other studies suggest that a low-phenylalanine diet can reduce blood phenylalanine levels. The review includes four studies, but we were not able to combine many results. Results from one study showed that blood phenylalanine levels were lower and intelligent quotient higher for people on a special diet. We recommend that a low-phenylalanine diet should be followed from the time of diagnosis. More research is needed to show if it is safe to relax this diet later on.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-08-10 09:37:45 +0100" MODIFIED_BY="Nikki Jahnke">
<ABS_BACKGROUND>
<P>Phenylketonuria is an inherited disease treated with dietary restriction of the amino acid phenylalanine. The diet is initiated in the neonatal period to prevent mental handicap; however, it is restrictive and can be difficult to follow. Whether the diet can be relaxed or discontinued during adolescence or should be continued for life remains a controversial issue, which we aim to address in this review.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effects of a low-phenylalanine diet commenced early in life for people with phenylketonuria. To assess the possible effects of relaxation or termination of the diet on intelligence, neuropsychological outcomes and mortality, growth, nutritional status, eating behaviour and quality of life.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-08-10 09:36:36 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches, handsearches of relevant journals and abstract books of conference proceedings.</P>
<P>Most recent search of the Inborn Errors of Metabolism Trials Register: 05 March 2009.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomised or quasi-randomised controlled trials comparing a low-phenylalanine diet to relaxation or termination of dietary restrictions in people with phenylketonuria.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two authors independently assessed study eligibility and methodological quality, and subsequently extracted the data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-08-10 09:37:45 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We included four studies in this review (251 participants), and found few significant differences between treatment and comparison groups for the outcomes of interest. Blood phenylalanine levels were significantly lower in participants with phenylketonuria following a low-phenylalanine diet compared to those on a less restricted diet, mean difference (MD) at three months -698.67 (95% confidence interval (CI) -869.44 to -527.89). Intelligence quotient was significantly higher in participants who continued the diet than in those who stopped the diet, MD after 12 months 5.00 (95% CI 0.40 to 9.60). However, these results came from a single study.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>The results of non-randomised studies have concluded that a low-phenylalanine diet is effective in reducing blood phenylalanine levels and improving intelligence quotient and neuropsychological outcomes. We were unable to find any randomised controlled studies that have assessed the effect of a low-phenylalanine diet versus no diet from diagnosis. In view of evidence from non-randomised studies, such a study would be unethical and it is recommended that low-phenylalanine diet should be commenced at the time of diagnosis. There is uncertainty about the precise level of phenylalanine restriction and when, if ever, the diet should be relaxed. This should be addressed by randomised controlled studies.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-10-28 16:50:46 +0000" MODIFIED_BY="Nikki Jahnke">
<BACKGROUND MODIFIED="2008-11-06 11:13:03 +0000" MODIFIED_BY="Tracey Remmington">
<CONDITION MODIFIED="2008-11-06 11:11:37 +0000" MODIFIED_BY="Tracey Remmington">
<P>Phenylketonuria (PKU) is an inherited disease which affects 100 cases per million live births in Caucasian and Asian populations (<LINK REF="REF-Scriver-1995" TYPE="REFERENCE">Scriver 1995</LINK>). PKU is characterised by an absence or deficiency of phenylalanine hydroxylase (a liver enzyme involved in the breakdown of the essential amino acid phenylalanine to tyrosine). In classical PKU there is a total, or almost total, deficiency of phenylalanine hydroxylase leading to high blood phenylalanine concentrations of 1200 &#956;mol/l or more (<LINK REF="REF-Scriver-1995" TYPE="REFERENCE">Scriver 1995</LINK>). In some cases blood phenylalanine concentrations are persistently raised above 400 &#956;mol/l, but not to the levels seen in classical PKU, although some degree of phenylalanine hydroxylase activity remains present. These conditions are called the hyperphenylalaninaemias. However, for the purpose of this review the term PKU will be used to include both classical PKU and the hyperphenylalaninaemias.</P>
<P>In infants with PKU, the blood phenylalanine concentration is within the normal range at birth, but becomes elevated, usually within several hours to a few days of commencing a normal dietary intake. This can lead to neurological damage and mental retardation if left untreated (<LINK REF="REF-Paine-1957" TYPE="REFERENCE">Paine 1957</LINK>). In infants with less severe phenylalanine hydroxylase deficiency the occurrence of brain damage is more variable.</P>
</CONDITION>
<INTERVENTION MODIFIED="2008-11-06 11:12:36 +0000" MODIFIED_BY="Tracey Remmington">
<P>The results of a number of cohort studies have indicated that dietary treatment of PKU is effective in preventing or reducing mental handicap, if initiated within the first twenty days of life (<LINK REF="REF-MRC1-1993" TYPE="REFERENCE">MRC1 1993</LINK>). However, the recommended diet has several disadvantages, as it is a difficult regimen to follow and requires regular support from a specialist team. In addition, the dietary restrictions may result in inappropriate eating behaviour patterns and nutritional deficiencies (<LINK REF="REF-Smith-1994" TYPE="REFERENCE">Smith 1994</LINK>). The aim of the diet is to achieve blood phenylalanine concentrations within the recommended levels and to promote normal growth and development (<LINK REF="REF-MRC1-1993" TYPE="REFERENCE">MRC1 1993</LINK>). This is achieved by the exclusion of high protein foods, which contain high concentrations of phenylalanine, for example meat, fish, cheese and eggs. However, phenylalanine is an essential amino acid and cannot be totally excluded from the diet. Therefore, the appropriate daily phenylalanine intake is provided by carefully measured quantities of foods containing lower concentrations of phenylalanine, for example, potatoes, baked beans and cereal products. These are called exchanges. The dietitian provides people with PKU and their families with a list of exchanges; the number of these varies according to the person's blood phenylalanine concentrations, which are regularly monitored. Foods that contain minimal amounts of phenylalanine, for example some fruits and vegetables, fats and sugar, can be taken freely. Special prescribable low-protein products are available in some countries to supplement the energy content and increase the variety of the diet. In addition to the dietary restrictions, people with PKU must consume a very low phenylalanine or phenylalanine-free amino acid supplement on a daily basis. This replaces the essential amino acids and other nutrients, which may be deficient in the restricted diet (<LINK REF="REF-Dixon-1994" TYPE="REFERENCE">Dixon 1994</LINK>). Care should be taken, as some of the amino acid supplements require additional supplementation with vitamins and minerals. In addition, these products are generally considered to be unpalatable; therefore close monitoring of compliance and the nutritional adequacy of the diet is essential to ensure adequate growth and to avoid nutritional deficiencies.</P>
<P>It is accepted that all children with PKU should be started on the diet as early as possible, but controversies exist around the issue of when, if at all, it is safe for dietary restrictions to be lifted or relaxed (<LINK REF="REF-Michals-1988" TYPE="REFERENCE">Michals 1988</LINK>). Previously, different recommendations have been made on the most appropriate age at which relaxation or discontinuation of the diet should occur, for example by the time the child with PKU has started school or when the child has reached early adolescence. However, recent research has indicated that older children and adults with PKU who have discontinued dietary restrictions may experience upper motor neurone disturbances (<LINK REF="REF-MRC2-1993" TYPE="REFERENCE">MRC2 1993</LINK>). Magnetic resonance imaging has also shown that high blood concentrations of phenylalanine in later childhood and adulthood can result in changes to the white matter of the brain (<LINK REF="REF-Smith-1994" TYPE="REFERENCE">Smith 1994</LINK>). In light of these studies, the Medical Research Council Working Party on Phenylketonuria issued a series of recommendations on the dietary management of PKU in the United Kingdom in 1993 (<LINK REF="REF-MRC1-1993" TYPE="REFERENCE">MRC1 1993</LINK>). Similar recommendations are followed in other countries (<LINK REF="REF-Fisch-1997" TYPE="REFERENCE">Fisch 1997</LINK>).</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2008-11-06 11:12:08 +0000" MODIFIED_BY="Tracey Remmington">
<P>People with PKU have received inconsistent advice about when to stop or relax dietary treatment since Bickel first introduced the diet (<LINK REF="REF-Bickel-1953" TYPE="REFERENCE">Bickel 1953</LINK>). This has resulted in a population of people with PKU who have followed a variety of levels of dietary restrictions over differing lengths of time.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-09-21 09:32:24 +0100" MODIFIED_BY="Nikki Jahnke">
<P>The aim of this review is to examine evidence that in people with PKU:</P>
<OL>
<LI>a low-phenylalanine diet started early in infancy improves neuropsychological performance and intelligence, and affects a number of other outcomes (listed under 'Types of outcome measures' below);</LI>
<LI>relaxation or discontinuation of dietary treatment in PKU has an adverse effect on neuropsychological performance and intelligence, and a number of other outcomes (listed under '<LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>' below).</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2009-09-21 09:57:53 +0100" MODIFIED_BY="Nikki Jahnke">
<SELECTION_CRITERIA MODIFIED="2009-08-06 10:54:48 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>Randomised controlled trials (RCTs), both published and unpublished. Trials, where quasi-randomisation methods such as alternation are used, will be included in future updates of this review if there is sufficient evidence that the treatment and comparison groups were comparable in terms of clinical and nutritional status.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Individuals of any age with phenylketonuria and other forms of phenylalanine hydroxylase deficiency, diagnosed by the Guthrie test or another recognised, validated screening test and in whom dietary intervention was commenced early in life.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Restriction of dietary phenylalanine and administration of phenylalanine-free or very low phenylalanine amino acid supplement initiated early in life as advised by a specialist PKU team and either continued for life or relaxed or discontinued at any point during the life of the person with PKU. This intervention being compared to unrestricted diet or less strict levels of phenylalanine restriction (with or without administration of very low phenylalanine or phenylalanine-free amino acid supplements). </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-08-06 10:54:48 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-08-06 10:54:48 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Blood phenylalanine concentration</LI>
<LI>Measures of neuropsychological performance</LI>
<LI>Measures of intelligence</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-08-06 10:54:11 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Blood tyrosine concentration</LI>
<LI>Weight gain or body mass index or z scores or centiles or other indices of nutritional status or growth</LI>
<LI>Energy and nutrient intake</LI>
<LI>Measures of eating behaviour</LI>
<LI>Measures of quality of life</LI>
<LI>Death</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-08-10 09:36:50 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Relevant studies were identified from the Group's Inborn Errors of Metabolism Trials Register using the term: diet.</P>
<P>The Inborn Errors of Metabolism Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (Clinical Trials) (updated each new issue of <I>The Cochrane Library</I>), quarterly searches of MEDLINE and the prospective handsearching of one journal - <I>Journal of Inherited Metabolic Disease</I>. Unpublished work was identified by searching through the abstract books of the Society for the Study of Inborn Errors of Metabolism conference and the SHS Inborn Error Review Series. For full details of all searching activities for the register, please see the relevant section of the Cystic Fibrosis and Genetic Disorders Group Module.</P>
<P>Additional RCTs were found from reference lists. Manufacturers of the phenylalanine-free and very low phenylalanine protein supplements were contacted to ask if they had data from published and unpublished RCTs on file.</P>
<P>Date of the most recent search of the Group's Inborn Errors of Metabolism Trials Register: 05 March 2009.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-09-21 09:57:53 +0100" MODIFIED_BY="Nikki Jahnke">
<STUDY_SELECTION MODIFIED="2008-11-06 15:58:29 +0000" MODIFIED_BY="Tracey Remmington">
<P>The two authors independently selected the studies to be included in the review. </P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-11-06 16:44:55 +0000" MODIFIED_BY="Tracey Remmington">
<P>Both authors independently extracted data.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-09-21 09:57:53 +0100" MODIFIED_BY="Nikki Jahnke">
<P>The two authors independently assessed the methodological quality of the included studies using a method described by Schulz (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>) and related this to the risk of bias. This method focuses on four areas: allocation concealment; generation of the randomisation sequence; intention-to-treat analysis; and blinding. The authors graded the concealment of allocation to the investigators of participants to treatment groups as being adequate, unclear or inadequate. The authors also used the same three categories to assess the method used to generate the randomisation sequence. In both cases, an 'adequate' grade related to a low risk of bias, an 'unclear' grade related to an unclear risk of bias and an 'inadequate' grade related to a high risk of bias. Use of an intention-to-treat analysis was assessed using the categories: adequate; unclear; or exclusions (i.e. participants were excluded from the final analysis), where adequate related to a low risk of bias, unclear to an unclear risk of bias and exclusions to a high risk of bias. The authors considered the level of blinding, although they noted that it is difficult to blind participants when treatment involves dietary manipulation. However, it should be possible for the investigators to be blinded to which treatment group the participant is in, even if the participant is aware of group allocation. The more people that were blinded to an intervention led to a lower risk of bias. Had the two authors disagreed about the quality of a study, then they would have resolved the disagreement by discussion until they reached a consensus.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2008-11-07 11:17:18 +0000" MODIFIED_BY="Tracey Remmington">
<P>For binary outcome measures we planned to calculate a pooled estimate of the treatment effect for each outcome across studies, (the odds of an outcome among treatment allocated participants to the corresponding odds among controls). For continuous outcomes, we recorded either mean change from baseline for each group or mean post-treatment or intervention values and standard deviation or standard error for each group. Where possible, we calculated a pooled estimate of treatment effect by calculating the mean difference (MD) with 95% confidence intervals (CI).</P>
<P>Outcome data were grouped into those measured at one, three, six, twelve months and annually thereafter. If outcome data are recorded at other time periods, we would consider examining these as well.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2008-11-06 16:48:29 +0000" MODIFIED_BY="Tracey Remmington">
<P>Where the authors included studies of cross-over design in the review, they ideally used paired data in the analysis to allow a within-individual comparison of the intervention. Where such data were not available, the authors used data from the first arm of the study only in the analysis. If this was not possible, they employed an unsatisfactory approach of using the combined results, thereby ignoring the cross-over design (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2008-11-06 16:47:19 +0000" MODIFIED_BY="Tracey Remmington">
<P>In order to allow an intention-to-treat analysis, we will seek data on the number of participants by allocated treatment group, irrespective of compliance and whether or not the participant was later thought to be ineligible or otherwise excluded from treatment or follow up.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2008-11-06 16:02:07 +0000" MODIFIED_BY="Tracey Remmington">
<P>The authors planned to test for heterogeneity between study results, using a standard chi-squared test.</P>
</HETEROGENEITY_ASSESSMENT>
<SUBGROUP_ANALYSIS MODIFIED="2008-11-06 16:01:54 +0000" MODIFIED_BY="Tracey Remmington">
<P>The authors may perform subgroup analysis (stratifying according to type of control group(s) used, age and level of dietary restriction) for future updates.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-11-06 16:01:53 +0000" MODIFIED_BY="Tracey Remmington">
<P>The authors planned to perform a sensitivity analysis based on the methodological quality of the studies, including and excluding quasi-randomised studies. </P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-10-28 16:50:46 +0000" MODIFIED_BY="Nikki Jahnke">
<STUDY_DESCRIPTION MODIFIED="2009-09-07 17:00:00 +0100" MODIFIED_BY="Nikki Jahnke">
<SEARCH_RESULTS MODIFIED="2009-09-07 16:58:32 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Thirty-nine references to twenty-two separate studies were identified in the searches.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2009-09-07 16:58:49 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We included four studies (19 references) in this review, with a total of 251 participants (<LINK REF="STD-Clarke-1987" TYPE="STUDY">Clarke 1987</LINK>; <LINK REF="STD-Griffiths-1998" TYPE="STUDY">Griffiths 1998</LINK>; <LINK REF="STD-Holtzman-1975" TYPE="STUDY">Holtzman 1975</LINK>; <LINK REF="STD-US_x002f_PKU-Collaborative" TYPE="STUDY">US/PKU Collaborative</LINK>). Two of these studies employed a cross-over design (<LINK REF="STD-Clarke-1987" TYPE="STUDY">Clarke 1987</LINK>; <LINK REF="STD-Griffiths-1998" TYPE="STUDY">Griffiths 1998</LINK>). Combined group data only were available from these two studies, which meant that the unsatisfactory approach of ignoring the cross-over design had to be employed to allow these data to be included in the analysis. The study by Holtzman investigated the effects of termination of low-phenylalanine diet at four years of age (<LINK REF="STD-Holtzman-1975" TYPE="STUDY">Holtzman 1975</LINK>). The study by Clarke looked at the effect of returning to low-phenylalanine diets in children who had previously relaxed their diet. It was noted that two of the participants who were included in the study had actually continued on a low-phenylalanine diet before starting the study (<LINK REF="STD-Clarke-1987" TYPE="STUDY">Clarke 1987</LINK>). The study by Griffiths investigated the effect of increasing phenylalanine intake in children who had continued on a low-phenylalanine diet since diagnosis (<LINK REF="STD-Griffiths-1998" TYPE="STUDY">Griffiths 1998</LINK>). The US/PKU collaborative study, a large, multicentre, randomised study, investigated the use of a strict low-phenylalanine diet compared to a moderately strict low-phenylalanine diet in newly diagnosed children with PKU (<LINK REF="STD-US_x002f_PKU-Collaborative" TYPE="STUDY">US/PKU Collaborative</LINK>). The majority of the children started the diet early in life; however, in some participants the diet was not initiated for up to 121 days, which would be considered late according to current recommendations. The participants were followed up regularly until their sixth birthdays, when half were randomised to continue the diet and half were randomised to terminate the diet. The participants then continued to be monitored until, in some cases, into adulthood.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2009-09-07 17:00:00 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Eighteen studies (20 references) were excluded from the review. Full details for the reasons for exclusion can be found in the tables (<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-10-28 16:50:46 +0000" MODIFIED_BY="Nikki Jahnke">
<ALLOCATION MODIFIED="2009-10-28 16:50:46 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Generation of randomisation sequence was adequate (with a low risk of bias) in only one of the included studies (<LINK REF="STD-US_x002f_PKU-Collaborative" TYPE="STUDY">US/PKU Collaborative</LINK>). In this study treatment groups were "randomly formed" using table of random numbers. Generation of randomisation sequence was unclear in the remaining three included studies leading to an unclear risk of bias for these studies (<LINK REF="STD-Clarke-1987" TYPE="STUDY">Clarke 1987</LINK>; <LINK REF="STD-Griffiths-1998" TYPE="STUDY">Griffiths 1998</LINK>; <LINK REF="STD-Holtzman-1975" TYPE="STUDY">Holtzman 1975</LINK>).</P>
<P>Allocation concealment was not discussed in two of the studies, which therefore had an unclear risk of bias (<LINK REF="STD-Clarke-1987" TYPE="STUDY">Clarke 1987</LINK>; <LINK REF="STD-Holtzman-1975" TYPE="STUDY">Holtzman 1975</LINK>). Allocation concealment was judged adequate in two studies; we therefore judged these studies to have a low risk of bias (<LINK REF="STD-Griffiths-1998" TYPE="STUDY">Griffiths 1998</LINK>; <LINK REF="STD-US_x002f_PKU-Collaborative" TYPE="STUDY">US/PKU Collaborative</LINK>). In the Griffiths study, the usual formula and experimental product were both prepared and coded by pharmaceutical company and the key to the code kept by a senior member of the hospital medical staff (<LINK REF="STD-Griffiths-1998" TYPE="STUDY">Griffiths 1998</LINK>). In the US PKU Collaborative study the allocation schedule was produced by project staff in telephone contact with local clinic staff at participating clinics (<LINK REF="STD-US_x002f_PKU-Collaborative" TYPE="STUDY">US/PKU Collaborative</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2009-09-21 11:50:48 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Two studies were triple-blind, which was achieved by the participants continuing on their usual diet but with the phenylalanine content of the diet manipulated by using additional supplements (<LINK REF="STD-Clarke-1987" TYPE="STUDY">Clarke 1987</LINK>; <LINK REF="STD-Griffiths-1998" TYPE="STUDY">Griffiths 1998</LINK>). We therefore judge these studies to have a low risk of bias for blinding of participants, clinicians and the outcome assessors. The other two studies did not blind the participants or the clinicians, but the outcome assessors were blinded to treatment groups; we therefore judge these to have a low risk of bias for the outcome assessors, but a high risk of bias from lack of blinding of the participants and clinicians (<LINK REF="STD-Holtzman-1975" TYPE="STUDY">Holtzman 1975</LINK>; <LINK REF="STD-US_x002f_PKU-Collaborative" TYPE="STUDY">US/PKU Collaborative</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2009-09-21 11:56:40 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Intention-to-treat analysis was employed in two of the studies, so we judged these to have a low risk of bias (<LINK REF="STD-Clarke-1987" TYPE="STUDY">Clarke 1987</LINK>; <LINK REF="STD-Griffiths-1998" TYPE="STUDY">Griffiths 1998</LINK>). We judge the other two studies to have an unclear risk of bias, since there were several drop outs from the studies, but reasons for these were briefly described in the published papers (<LINK REF="STD-Holtzman-1975" TYPE="STUDY">Holtzman 1975</LINK>; <LINK REF="STD-US_x002f_PKU-Collaborative" TYPE="STUDY">US/PKU Collaborative</LINK>). In one study, data on some of the participants were missing at several of the intermediate time points and at the end of the study (<LINK REF="STD-Holtzman-1975" TYPE="STUDY">Holtzman 1975</LINK>). In the US PKU study, a relatively high proportion of participants were lost to follow up and some participants swapped groups after randomisation (<LINK REF="STD-US_x002f_PKU-Collaborative" TYPE="STUDY">US/PKU Collaborative</LINK>). In addition, many of the study reports combine the results of the groups. This makes analysis difficult or impossible. We have contacted the principal investigator to obtain further details of the individual patient data; however, as yet, this has been unsuccessful.</P>
</EXCLUSIONS>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-11-07 11:17:36 +0000" MODIFIED_BY="Tracey Remmington">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Blood phenylalanine concentration</HEADING>
<P>This outcome was measured in all of the studies. The US/PKU collaborative study measured this outcome on a regular basis for up to 12 years (<LINK REF="STD-US_x002f_PKU-Collaborative" TYPE="STUDY">US/PKU Collaborative</LINK>). The analysis shows that blood phenylalanine concentrations were significantly lower in the participants on the low-phenylalanine diet than those on a less restricted diet; MD at three months was -698.67 (95% CI -869.44 to - 527.89), based on the results of two studies. In the study comparing a low-phenylalanine diet to a less restricted diet from diagnosis, the blood phenylalanine concentrations were significantly lower in the participants on the low-phenylalanine diet. However, these results are based on only one study (<LINK REF="STD-US_x002f_PKU-Collaborative" TYPE="STUDY">US/PKU Collaborative</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Blood tyrosine concentration</HEADING>
<P>This outcome was not measured in any of the studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Weight gain and other measures of nutritional status</HEADING>
<P>This outcome was measured in only two studies (<LINK REF="STD-Holtzman-1975" TYPE="STUDY">Holtzman 1975</LINK>; <LINK REF="STD-US_x002f_PKU-Collaborative" TYPE="STUDY">US/PKU Collaborative</LINK>). The US/PKU collaborative study measured weight, height and head circumference of participants over four years (<LINK REF="STD-US_x002f_PKU-Collaborative" TYPE="STUDY">US/PKU Collaborative</LINK>). Unfortunately, they only reported the combined results of the treatment and control groups, but we are trying to obtain the individual data from the trialists. However, data were available on weights of the two groups of participants for the first year. In the study by Holtzman, the number of participants in each group was very small and no standard deviations were reported (<LINK REF="STD-Holtzman-1975" TYPE="STUDY">Holtzman 1975</LINK>). It was reported that height and head circumference data were also collected in this study, although the data were not presented in the published report. No significant differences were found between mean weights of the two groups at any time point.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Neuropsychological performance</HEADING>
<P>More than 30 different assessments of neuropsychological performance were carried out in the four studies. Only three of the measures were used in more than one study, although final data from these assessments were not available. Therefore, this outcome was not assessed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Intelligence quotient</HEADING>
<P>Three of the studies assessed intelligence quotient (IQ) (<LINK REF="STD-Clarke-1987" TYPE="STUDY">Clarke 1987</LINK>; <LINK REF="STD-Holtzman-1975" TYPE="STUDY">Holtzman 1975</LINK>; <LINK REF="STD-US_x002f_PKU-Collaborative" TYPE="STUDY">US/PKU Collaborative</LINK>). One study did not report the results of the IQ test, although we have contacted the trialists to gain further information (<LINK REF="STD-Clarke-1987" TYPE="STUDY">Clarke 1987</LINK>). Another study did not provide standard deviations for the results (<LINK REF="STD-Holtzman-1975" TYPE="STUDY">Holtzman 1975</LINK>). The US/PKU collaborative study found no significant difference between the IQ of participants, who were initiated on a strict low-phenylalanine diet at diagnosis, compared to those who received a less strict low-phenylalanine diet from diagnosis (<LINK REF="STD-US_x002f_PKU-Collaborative" TYPE="STUDY">US/PKU Collaborative</LINK>). However, following the second randomisation at six years of age, those participants who were randomised to continue the low-phenylalanine diet achieved a higher IQ than those who were randomised to discontinue the diet. This result was significant after 12 months, MD 5.00 (95% CI 0.40 to 9.60).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Energy &amp; protein intake</HEADING>
<P>Energy and protein intake were assessed in only one of the studies; no significant differences were found between the treatment and comparison groups (<LINK REF="STD-US_x002f_PKU-Collaborative" TYPE="STUDY">US/PKU Collaborative</LINK>). This study also assessed median phenylalanine intakes over six-monthly periods between the ages of 15 months and 6 years. The children in the group receiving the strictly controlled diet had significantly lower median phenylalanine intakes than those on the less strictly controlled diet. It should be noted that these results are based on data from one study only (<LINK REF="STD-US_x002f_PKU-Collaborative" TYPE="STUDY">US/PKU Collaborative</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Eating behaviour</HEADING>
<P>This outcome was not measured in any of the studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Quality of life</HEADING>
<P>This outcome was not measured in any of the studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Mortality</HEADING>
<P>This outcome was not measured in any of the studies.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>The recommended diet for the treatment of PKU is very restricted. This has implications for the nutritional status, growth and quality of life of people with PKU. Due to the relatively small numbers of people with PKU, most studies involve only small numbers of participants. This is reflected in the studies considered in this review, with the maximum number of participants in a study being 216, although the data from all these participants were not included in the published report (<LINK REF="STD-US_x002f_PKU-Collaborative" TYPE="STUDY">US/PKU Collaborative</LINK>). Several of the included studies did not provide details on allocation concealment or generation of randomisation sequence. Only two of the four studies employed an intention-to-treat analysis (<LINK REF="STD-Clarke-1987" TYPE="STUDY">Clarke 1987</LINK>; <LINK REF="STD-Griffiths-1998" TYPE="STUDY">Griffiths 1998</LINK>). As would be expected, blood phenylalanine concentration, which was assessed in all the studies, was found to be significantly higher in people with PKU on a relaxed phenylalanine diet than in those on a low-phenylalanine diet. The outcome measures used to assess neuropsychological performance varied from study to study, and it was therefore impossible to combine the results of the studies statistically. The published reports of these studies confounded the situation further by omitting some data. </P>
<P>Only one study investigated the effects of different levels of phenylalanine restriction commenced at diagnosis (<LINK REF="STD-US_x002f_PKU-Collaborative" TYPE="STUDY">US/PKU Collaborative</LINK>). This study failed to find any significant results other than for blood phenylalanine level and median phenylalanine intake during the first six years of the study. The second stage of this study, which assessed the effect of continuation or termination of the diet at six years of age, found a significant difference between the IQ of those participants who continued the diet compared to those who terminated the diet. This suggests that continuation of the low phenylalanine diet has a beneficial effect on IQ. The remaining studies also investigated the effect of terminating or re-commencing the diet at some point later in life, after the diet had been initiated at diagnosis, although we were unable to combine any further results for IQ with those of the US/PKU collaborative study (<LINK REF="STD-US_x002f_PKU-Collaborative" TYPE="STUDY">US/PKU Collaborative</LINK>). We know from sources of evidence other than RCTs, that a high proportion of children with PKU who do not receive any dietary manipulation develop mental handicap and neurological impairment (<LINK REF="REF-MRC2-1993" TYPE="REFERENCE">MRC2 1993</LINK>). It would thus be unethical to withhold treatment from people with PKU at diagnosis; however, it may be useful to study the level of restriction required from diagnosis in a study similar to that of the US/PKU collaborative study (<LINK REF="STD-US_x002f_PKU-Collaborative" TYPE="STUDY">US/PKU Collaborative</LINK>). It is disappointing that the studies available included only small numbers of participants and have not followed them into adulthood.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Due to the lack of good quality RCTs in this review, no conclusions can be drawn about the effectiveness of specific dietary interventions in PKU. As a result of the concerns about mental handicap and neurological damage in untreated PKU, current recommendations to commence a low-phenylalanine diet at diagnosis should continue to be observed. However, there is a lack of clear evidence about the precise level of phenylalanine restriction or when, if ever, the restricted diet could be relaxed. A large, well-designed, adequately-powered RCT is necessary to provide further information. Many centres would need to be involved to achieve this. Therefore, it is recommended that people with PKU should not be entered into small studies, which would then exclude them from entering into a larger study.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>A large, well-designed, adequately-powered, randomised, controlled, double-blind study is necessary to assess the effect of termination of dietary restrictions in PKU. Careful consideration should be given to the inclusion criteria. It may also be useful to assess the effect of different levels of dietary restrictions initiated from diagnosis. Due to the low incidence of PKU in the population, it is essential that any such study be multicentre and possibly international. It would be necessary to ascertain which outcome measures are most appropriate, and to reach a consensus on which measures of intelligence and neuropsychological performance should be used. It would also be beneficial if people with PKU, or their parents, could be involved in the design of the study to ensure that the most important and relevant aspects are considered.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-09-07 17:01:23 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We would like to thank Mrs Patricia Rutherford for her contribution to the original review and updates up until May 2007.</P>
<P>We thank the following experts in metabolic disease for commenting on the review:<BR/>Professor N Buist, Oregon, USA<BR/>Dr C Davidson, Liverpool, UK<BR/>Dr B Wilcken, Sydney, Australia<BR/>Professor R Koch, Los Angeles, USA<BR/>Dr I Smith, London, UK<BR/>Dr J Collins, London, UK<BR/>Dr J Walter, Manchester, UK</P>
<P>We also thank Dr D. Isherwood, Royal Liverpool Children's Hospital, UK, for assisting in the handsearching of the Journal of Inherited Metabolic Disease, and The British Dietetic Association for providing computer equipment used in the production of this review. We also thank Ms Vida Rahmani and Mrs Cathy Corlett for providing invaluable consumer input, and Professor F. Cockburn and Dr A. Harvie for providing additional trial data.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Vanessa Poustie and Patricia Rutherford have received travel expenses to attend conferences from the manufacturers of dietary products used in the treatment of PKU.<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-11-07 11:18:21 +0000" MODIFIED_BY="Tracey Remmington">
<P>For production of the initial review and the updates until 2006:</P>
<P>Vanessa Poustie:</P>
<OL>
<LI>identification of trials from Cochrane Cystic Fibrosis &amp; Genetic Disorders Group Trials Register;</LI>
<LI>handsearching of the Journal of Inherited Metabolic Disease from 1979 to 1998;</LI>
<LI>further identification of trials from publication reference lists;</LI>
<LI>selection of eligible trials;</LI>
<LI>assessment of trial methodology;</LI>
<LI>extraction of relevant data from the trials;</LI>
<LI>input of trial data;</LI>
<LI>production of the final review;</LI>
<LI>updating review.</LI>
</OL>
<P>Patricia Rutherford:</P>
<OL>
<LI>selection of eligible trials;</LI>
<LI>assessment of trial methodology;</LI>
<LI>extraction of relevant data from the trials;</LI>
<LI>comment on final draft of review;</LI>
<LI>comment on updates of review up to and including 2006 update.</LI>
</OL>
<P>Update 2007:<BR/>Vanessa Poustie remains as lead author and was involved in study selection.<BR/>Patricia Rutherford is no longer an active author on this review.<BR/>Joanne Wildgoose is now a new author on this review and was involved in study selection.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2008-11-06 10:59:38 +0000" MODIFIED_BY="Tracey Remmington">
<P>Within this review we have chosen to report the primary outcomes: blood phenylalanine concentration; and blood tyrosine concentration in micromol/l.</P>
<P>Therefore, we have used the following conversions on data reported in several of the primary papers that report mg/dl:</P>
<P>Phenylalanine - 1 mg/dl = 60.5 micromol/l<BR/>Tyrosine - 1 mg/dl = 55 micromol/l</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-09-07 16:51:51 +0100" MODIFIED_BY="Nikki Jahnke">
<STUDIES MODIFIED="2009-09-07 16:51:51 +0100" MODIFIED_BY="Nikki Jahnke">
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Clarke-1987" NAME="Clarke 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Clarke JTR, Gates RD, Hogan SE, Barrett M, MacDonald GW. Neuropsychological studies on adolescents with phenylketonuria returned to phenylalanine-restricted diets. Am J Ment Retard 1987; 92: 255-262.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clarke JTR, Gates RD, Hogan SE, Barrett M, MacDonald GW</AU>
<TI>Neuropsychological studies on adolescents with phenylketonuria returned to phenylalanine-restricted diets</TI>
<SO>American Journal of Mental Retardation</SO>
<YR>1987</YR>
<VL>92</VL>
<NO>3</NO>
<PG>255-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Griffiths-1998" NAME="Griffiths 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Griffiths P, Smith C, Harvie A. Transitory hyperphenylalaninaemia in children with continuously treated phenylketonuria. Am J Mental Retard 1997; 102: 27-36.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Griffiths P, Smith C, Harvie A</AU>
<TI>Transitory hyperphenylalaninaemia in children with continuously treated phenylketonuria</TI>
<SO>American Journal of Mental Retardation</SO>
<YR>1997</YR>
<VL>102</VL>
<NO>1</NO>
<PG>27-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Griffiths P, Ward N, Harvie A, Cockburn F. Neuropsychological outcome of experimental manipulation of phenylalanine intake in treated phenylketonuria. J Inherit Metab Dis 1998; 21: 29 - 38.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Griffiths P, Ward N, Harvie A, Cockburn F</AU>
<TI>Neuropsychological outcome of experimental manipulation of phenylalanine intake in treated phenylketonuria</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>1</NO>
<PG>29-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holtzman-1975" NAME="Holtzman 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Holtzman NA, Welcher DW, Mellits ED. Termination of restricted diet in children with phenylketonuria: a randomised controlled trial. N Engl J Med 1975; 293: 1121 - 1124.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holtzman NA, Welcher DW, Mellits ED</AU>
<TI>Termination of restricted diet in children with phenylketonuria: a randomised controlled study</TI>
<SO>New England Journal of Medicine</SO>
<YR>1975</YR>
<VL>293</VL>
<NO>22</NO>
<PG>1121-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-US_x002f_PKU-Collaborative" NAME="US/PKU Collaborative" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Acosta PB, Trahams C, Wellman NS, Williamson M</AU>
<TI>Phenylalanine intakes of 1- to 6-year old children with phenylketonuria undergoing therapy</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1983</YR>
<VL>38</VL>
<NO>5</NO>
<PG>694-700</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Acosta PB, Wentz E, Williamson M. Nutrient intake of treated infants with phenylketonuria. Am J Clin Nutr 1977; 30: 198-208.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Acosta PB, Wentz E, Williamson M</AU>
<TI>Nutrient intake of treated infants with phenylketonuria</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1977</YR>
<VL>30</VL>
<NO>2</NO>
<PG>198-208</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Azen C, Koch R, Friedman E, Wenz E, Fishler K. Summary of findings from the United States Collaborative Study of children treated for phenylketonuria. Eur J Pediatr 1996; 155 [Suppl 1]: S29-S32.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Azen C, Koch R, Friedman E, Wenz E, Fishler K</AU>
<TI>Summary of findings from the United States Collaborative Study of children treated for phenylketonuria</TI>
<SO>European Journal of Pediatrics</SO>
<YR>1996</YR>
<VL>155</VL>
<NO>Suppl 1</NO>
<PG>S29-S32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Azen CG, Koch R, Friedman EG, Berlow S, Coldwell J, Krause W, Matalon R, McCabe E, O'Flynn M, Peterson R, Rouse B, Scott CR, Sigman B, Valle D, Warner R. Intellectual development in 12 year old children treated for phenylketonuria. Am J Dis Child 1991; 145: 35-39.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Azen CG, Koch R, Friedman EG, Berlow S, Coldwell J, Krause W, et al</AU>
<TI>Intellectual development in 12-year-old children treated for phenylketonuria</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1991</YR>
<VL>145</VL>
<NO>1</NO>
<PG>35-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Dobson JC, Williamson ML, Azen C, Koch R. Intellectual assessment of 111 four-year-old children with phenylketonuria. Pediatrics 1977; 60: 822-827.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dobson JC, Williamson ML, Azen C, Koch R</AU>
<TI>Intellectual assessment of 111 four-year-old children with phenylketonuria</TI>
<SO>Pediatrics</SO>
<YR>1977</YR>
<VL>60</VL>
<NO>6</NO>
<PG>822-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fishler K, Azen CG, Friedman EG, Koch R</AU>
<TI>School achievement in treated PKU children</TI>
<SO>Journal of Mental Deficiency Research</SO>
<YR>1989</YR>
<VL>33</VL>
<NO>Pt 6</NO>
<PG>493-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Holm VA, Kronmal RA, Williamson M, Roche AF. Physical growth in phenylketonuria: II. Growth of treated children in the PKU collaborative study from birth to 4 years of age. Pediatrics 1979, 63; 700.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holm VA, Kronmal RA, Williamson M, Roche AF</AU>
<TI>Physical growth in phenylketonuria: II. Growth of treated children in the PKU collaborative study from birth to 4 years of age</TI>
<SO>Pediatrics</SO>
<YR>1979</YR>
<VL>63</VL>
<NO>5</NO>
<PG>700-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Koch R, Azen C, Friedman EG, Williamson ML. Paired comparison between early treated PKU children and their matched sibling controls on intelligence and school achievement test results at eight years of age. J Inher Metab Dis 1984; 7: 86-90.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koch R, Azen C, Friedman EG, Williamson ML</AU>
<TI>Paired comparisons between early treated PKU children and their matched sibling controls on intelligence and school achievement test results at eight years of age</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>1984</YR>
<VL>7</VL>
<NO>2</NO>
<PG>86-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Koch R, Azen CG, Friedman EG, Williamson ML. Preliminary report on the effects of diet discontinuation in PKU. J Pediatr 1982; 100: 870-875.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koch R, Azen CG, Friedman EG, Williamson ML</AU>
<TI>Preliminary report on the effects of diet discontinuation in PKU</TI>
<SO>Journal of Pediatrics</SO>
<YR>1982</YR>
<VL>100</VL>
<NO>4</NO>
<PG>870-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koch R, Burton B, Hoganson G, Peterson R, Rhead W, Rouse B, et al</AU>
<TI>Phenylketonuria in adulthood: a collaborative study</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>5</NO>
<PG>333-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Koch R, Friedman E, Williamson M, Azen C, Blaskovics, Parker G. Report from the U.S. Collaborative Study of diet discontinuation in PKU children. .&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Koch R, Friedman E, Williamson M, Azen C, Blaskovics, Parker G</AU>
<TI>Report from the U.S. Collaborative Study of diet discontinuation in PKU children [abstract]</TI>
<SO>Proceedings from the 19th International Conference of the Society for the Study of Inborn Errors of Metabolsm;1981; Southampton</SO>
<YR>1981</YR>
<PG>No. 6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Koch R, Friedman EG, Williamson ML, Azen CG. Preliminary report of the effects of diet discontinuation in phenylketonuria. J Inher Metab Dis 1982; 5 Suppl 1: 63-64.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koch R, Friedman EG, Williamson ML, Azen CG</AU>
<TI>Preliminary report of the effects of diet discontinuation in phenylketonuria</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>1982</YR>
<VL>5</VL>
<NO>Suppl 1</NO>
<PG>63-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Williamson M, Dobson JC, Koch R. Collaborative study of children treated for phenylketonuria: study design. Pediatrics 1977; 60: 815-821.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Williamson M, Dobson JC, Koch R</AU>
<TI>Collaborative study of children treated for phenylketonuria: study design</TI>
<SO>Pediatrics</SO>
<YR>1977</YR>
<VL>60</VL>
<NO>6</NO>
<PG>815-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Williamson ML, Koch R, Azen C, Chang C. Correlates of intelligence test results in treated phenylketonuric children. Conference proceedings of the 19th International Meeting of the Society for the Study of Inborn Errors of Metabolism, 1981.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Williamson ML, Koch R, Azen C, Chang C</AU>
<TI>Correlates of intelligence test results in treated phenylketonuric children [abstract]</TI>
<SO>Proceedings of the 19th International Meeting of the Society for the Study of Inborn Errors of Metabolism; 1981; Southampton</SO>
<YR>1981</YR>
<PG>No. 43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Williamson ML, Koch R, Azen C, Chang C. Correlates of intelligence test results in treated phenylketonuric children. Pediatrics 1981; 68: 161-167.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Williamson ML, Koch R, Azen C, Chang C</AU>
<TI>Correlates of intelligence test results in treated phenylketonuric children</TI>
<SO>Pediatrics</SO>
<YR>1981</YR>
<VL>68</VL>
<NO>2</NO>
<PG>161-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-09-07 16:51:51 +0100" MODIFIED_BY="Nikki Jahnke">
<STUDY DATA_SOURCE="PUB" ID="STD-Bentovim-1968" NAME="Bentovim 1968" YEAR="1968">
<REFERENCE NOTES="&lt;p&gt;Bentovim A. Controlled observations of phenylketonuric children on and during withdrawal from low phenylalanine diet. Arch Dis Child 1968; 43: 745-746.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bentovim A</AU>
<TI>Controlled observations of phenylketonuric children on and during withdrawal from low phenylalanine diet</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1968</YR>
<VL>43</VL>
<NO>232</NO>
<PG>745-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cleary-2006" MODIFIED="2009-08-10 09:22:26 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Cleary 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-08-10 09:22:26 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cleary MA, Feillet F, White FJ, Vidailhet M, Macdonald A, Grimsley A, et al</AU>
<TI>Randomised controlled trial of essential fatty acid supplementation in phenylketonuria</TI>
<SO>European Journal of Clinical Nutrition</SO>
<YR>2006</YR>
<VL>60</VL>
<NO>7</NO>
<PG>915-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98240314"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Epstein-1989" NAME="Epstein 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Epstein CM, Trotter JF, Averbook A, Freeman S, Kutner MH, Elsas LJ</AU>
<TI>EEG mean frequencies are sensitive indices of phenylalanine effects on normal brain</TI>
<SO>Electroencephalography and Clinical Neurophysiology</SO>
<YR>1989</YR>
<VL>72</VL>
<NO>2</NO>
<PG>133-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frankenburg-1973" NAME="Frankenburg 1973" YEAR="1973">
<REFERENCE NOTES="&lt;p&gt;Frankenburg WK, Goldstein AD. Behavioural consequences of increased phenylalanine intake by phenylketonuric children: a pilot study describing a methodology. Am J Ment Defic 1973; 77: 524-532.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frankenburg WK, Goldstein AD</AU>
<TI>Behavioural consequences of increased phenylalanine intake by phenylketonuric children: a pilot study describing a methodology</TI>
<SO>American Journal of Mental Deficiency</SO>
<YR>1973</YR>
<VL>77</VL>
<NO>5</NO>
<PG>524-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kakanoglu-2005" MODIFIED="2009-08-10 09:11:09 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Kakanoglu 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-08-10 09:11:08 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalkanoglu HS, Ahring KK, Sertkaya D, Moller LB, Romstad A, Mikkelsen I, et al</AU>
<TI>Behavioural effects of phenylalanine-free amino acid tablet supplementation in intellectually disabled adults with untreated phenylketonuria</TI>
<SO>Act Paediatrica</SO>
<YR>2005</YR>
<VL>94</VL>
<NO>9</NO>
<PG>1218-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koff-1979" NAME="Koff 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Koff E, Kammerer B, Boyle P, Pueschel SM. Intelligence and phenylketonuria: effects of diet termination. J Pediatr 1979; 94: 534-537.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koff E, Kammerer B, Boyle P, Pueschel SM</AU>
<TI>Intelligence and phenylketonuria: effects of diet termination</TI>
<SO>Journal of Pediatrics</SO>
<YR>1979</YR>
<VL>94</VL>
<NO>4</NO>
<PG>534-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koletzko-2007" MODIFIED="2009-08-10 09:19:33 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Koletzko 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-10 09:19:33 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koletzko B, Sauerwald T, Demmelmair H, Herzog M, von Schenck U, Bohles H, et al</AU>
<TI>Dietary long-chain polyunsaturated fatty acid supplementation in infants with phenylketonuria: a randomized controlled trial</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>2007</YR>
<VL>30</VL>
<NO>3</NO>
<PG>326-32</PG>
<IDENTIFIERS MODIFIED="2009-08-10 09:19:32 +0100" MODIFIED_BY="Nikki Jahnke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krause-1985" NAME="Krause 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Krause W, Halminski M, McDonald L, Dembure P, Salvo R, Freides D, Elsas L. Biochemical and neuropsychological effects of elevated plasma phenylalanine in patients with treated phenylketonuria. A model for the study of phenylalanine and brain function in man. J Clin Invest 1985; 75: 40-48.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krause W, Halminski M, McDonald L, Dembure P, Salvo R, Freides D, et al</AU>
<TI>Biochemical and neuropsychological effects of elevated plasma phenylalanine in patients with treated phenylketonuria. A model for the study of phenylalanine and brain function in man.</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>1985</YR>
<VL>75</VL>
<NO>1</NO>
<PG>40-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levy-2007" MODIFIED="2009-08-10 09:14:35 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Levy 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-10 09:14:32 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levy HL, Milanowski A, Chakrapani A, Cleary M, Lee P, Trefz FK, et al</AU>
<TI>Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study</TI>
<SO>Lancet</SO>
<YR>2007</YR>
<VL>370</VL>
<NO>9586</NO>
<PG>504-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lou-1987" MODIFIED="2009-09-07 16:51:51 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Lou 1987" YEAR="1987">
<REFERENCE MODIFIED="2009-09-07 16:51:51 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lou HC, Lykkelund C, Gerdes AM, Udesen H, Bruhn P</AU>
<TI>Increased vigilance and dopamine synthesis by large doses of tyrosine or phenylalanine restriction in phenylketonuria</TI>
<SO>Acta Paediatrica Scandinavica</SO>
<YR>1987</YR>
<VL>76</VL>
<NO>4</NO>
<PG>560-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="87322369"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pietz-1995" MODIFIED="2009-08-10 09:20:44 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Pietz 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-08-10 09:20:44 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pietz J, Landwehr R, Kutscha A, Schmidt H, de Sonneville L, Trefz FK</AU>
<TI>Effect of high-dose tyrosine supplementation on brain function in adults with phenylketonuria</TI>
<SO>Journal of Pediatrics</SO>
<YR>1995</YR>
<VL>127</VL>
<NO>6</NO>
<PG>936-43</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="96101714"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Realmuto-1986" NAME="Realmuto 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Realmuto GM, Garfinkel BD, Tuchman M, Tsai MY, Chang PN, Fisch RO, et al</AU>
<TI>Psychiatric diagnosis and behavioural characteristics of phenylketonuric children</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1986</YR>
<VL>174</VL>
<NO>9</NO>
<PG>536-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rey-1996" NAME="Rey 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Rey F, Abadie V, Plainguet F, Rey J. Long-term follow up of patients with classical phenylketonuria after diet relaxation at 5 years of age. Eur J Pediatr 1996; 155 [Suppl 1]: S39-S44.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rey F, Abadie V, Plainguet F, Rey J</AU>
<TI>Long-term follow up of patients with classical phenylketonuria after diet relaxation at 5 years of age</TI>
<SO>European Journal of Pediatrics</SO>
<YR>1996</YR>
<VL>155</VL>
<NO>Suppl 1</NO>
<PG>S39-S44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robertson-2004" MODIFIED="2009-08-10 09:29:25 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Robertson 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Robertson L, Lee P, Murphy G, Amos A</AU>
<TI>A trial to assess the effectiveness of a low phenylalanine diet in adults with previously untreated phenylketonuria (PKU) [abstract]</TI>
<SO>SHS Inborn Error Review Series (Dietary Management of Inborn Errors of Metabolic Disease)</SO>
<YR>2004</YR>
<VL>14</VL>
<PG>10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robertson L, Lee P, Murphy G, Amos A</AU>
<TI>A trial to assess the effectiveness of a low phenylalanine diet in adults with previously untreated phenylketonuria (PKU) [abstract]</TI>
<SO>SHS Inborn Error Review Series (Dietary Management of Inborn Errors of Metabolic Disease)</SO>
<YR>2004</YR>
<VL>14</VL>
<PG>18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-08-10 09:29:25 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Robertson L, Murphy G, Amos A, Lee P, Dent C</AU>
<TI>A randomised control trial of diet in adults with previously untreated phenylketonuria (PKU) [abstract]</TI>
<SO>Dietary Management of Inherited Metabolic Disease (DMIMD); 2008 April 17-18th; London, UK</SO>
<YR>2008</YR>
<PG>36</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98240314"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schindeler-2007" MODIFIED="2009-09-07 16:51:46 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Schindeler 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-09-07 16:51:46 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schindeler S, Ghosh-Jerath S, Thompson S, Rocca A, Joy P, Kemp A, et al</AU>
<TI>The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study</TI>
<SO>Molecular Genetics and Metabolism</SO>
<YR>2007</YR>
<VL>91</VL>
<NO>1</NO>
<PG>48-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmidt-1994" NAME="Schmidt 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Schmidt E, Rupp A, Burgard P, Pietz J, Weglage J, de Sonneville L. Sustained attention in adult phenylketonuria: the influence of the concurrent phenylalanine blood level. J Clin Exp Neuro 1994; 16: 681-688.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt E, Rupp A, Burgard P, Pietz J, Weglage J, de Sonneville L</AU>
<TI>Sustained attention in adult phenylketonuria: the influence of the concurrent phenylalanine blood level</TI>
<SO>Journal of Clinical Experimental Neuropsychology</SO>
<YR>1994</YR>
<VL>16</VL>
<NO>5</NO>
<PG>681-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmidt-1996" NAME="Schmidt 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Schmidt E, Burgard P, Rupp A. Effects of concurrent phenylalanine levels on sustained attention and calculation speed in patients treated early for phenylketonuria. Eur J Pediatr 1996; 155[Suppl 1]: S82-S86.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt E, Burgard P, Rupp A</AU>
<TI>Effects of concurrent phenylalanine levels on sustained attention and calculation speed in patients treated early for phenylketonuria</TI>
<SO>European Journal of Pediatrics</SO>
<YR>1996</YR>
<VL>155</VL>
<NO>Suppl 1</NO>
<PG>S82-S86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1998" MODIFIED="2009-08-10 09:21:27 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Smith 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-08-10 09:21:27 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith ML, Hanley WB, Clarke JT, Klim P, Schoonheyt W, Austin V, et al</AU>
<TI>Randomised controlled trial of tyrosine supplementation on neuropsychological performance in phenylketonuria</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1998</YR>
<VL>78</VL>
<NO>2</NO>
<PG>116-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98240314"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-09-07 16:51:51 +0100" MODIFIED_BY="Nikki Jahnke"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-08-10 09:27:38 +0100" MODIFIED_BY="Nikki Jahnke">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-07 11:26:58 +0000" MODIFIED_BY="Tracey Remmington">
<REFERENCE ID="REF-Bickel-1953" MODIFIED="2008-11-07 11:26:58 +0000" MODIFIED_BY="Tracey Remmington" NAME="Bickel 1953" TYPE="JOURNAL_ARTICLE">
<AU>Bickel H</AU>
<TI>Influence of phenylalanine intake on phenylketonuria</TI>
<SO>Lancet</SO>
<YR>1953</YR>
<VL>2</VL>
<PG>812-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dixon-1994" MODIFIED="2008-11-07 11:26:30 +0000" MODIFIED_BY="Tracey Remmington" NAME="Dixon 1994" TYPE="BOOK_SECTION">
<AU>Dixon M</AU>
<TI>Disorders of amino acid metabolism, organic acidaemias and uria cycle defects</TI>
<SO>Clinical Paediatric Dietetics</SO>
<YR>1994</YR>
<PG>177-209</PG>
<EN>1st</EN>
<ED>Shaw V, Lawson M</ED>
<PB>Blackwell Science</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fisch-1997" MODIFIED="2008-11-07 11:26:32 +0000" MODIFIED_BY="Tracey Remmington" NAME="Fisch 1997" TYPE="JOURNAL_ARTICLE">
<AU>Fisch RO, Matalon R, Weisberg S, Michals K</AU>
<TI>Phenylketonuria: Current dietary treatment practices in the United States and Canada</TI>
<SO>Journal of the American College of Nutrition</SO>
<YR>1997</YR>
<VL>16</VL>
<NO>2</NO>
<PG>147-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Michals-1988" MODIFIED="2008-11-07 11:26:34 +0000" MODIFIED_BY="Tracey Remmington" NAME="Michals 1988" TYPE="JOURNAL_ARTICLE">
<AU>Michals K, Azen C, Acosta P, Koch R, Matalon R</AU>
<TI>Blood phenylalanine levels and intelligence of 10 year old children with PKU in the National Collaborative Study</TI>
<SO>Journal of the American Dietetic Association</SO>
<YR>1988</YR>
<VL>88</VL>
<NO>10</NO>
<PG>1226-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MRC1-1993" MODIFIED="2008-11-07 11:26:37 +0000" MODIFIED_BY="Tracey Remmington" NAME="MRC1 1993" TYPE="JOURNAL_ARTICLE">
<AU>Medical Research Council Working Party on Phenylketonuria</AU>
<TI>Recommendations on the dietary management of phenylketonuria</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1993</YR>
<VL>68</VL>
<NO>3</NO>
<PG>426-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MRC2-1993" MODIFIED="2008-11-07 11:26:39 +0000" MODIFIED_BY="Tracey Remmington" NAME="MRC2 1993" TYPE="JOURNAL_ARTICLE">
<AU>Medical Research Council Working Party on Phenylketonuria</AU>
<TI>Phenylketonuria due to phenylalanine hydroxylase deficiency: an unfolding story</TI>
<SO>British Medical Journal</SO>
<YR>1993</YR>
<VL>306</VL>
<NO>6870</NO>
<PG>115-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paine-1957" MODIFIED="2008-11-07 11:26:45 +0000" MODIFIED_BY="Tracey Remmington" NAME="Paine 1957" TYPE="JOURNAL_ARTICLE">
<AU>Paine RS</AU>
<TI>The variability and manifestations of untreated patients with phenylketonuria (phenylpyruvic aciduria)</TI>
<SO>Pediatrics</SO>
<YR>1957</YR>
<VL>20</VL>
<PG>290-302</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2008-11-07 11:26:50 +0000" MODIFIED_BY="Tracey Remmington" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scriver-1995" MODIFIED="2008-11-07 11:26:49 +0000" MODIFIED_BY="Tracey Remmington" NAME="Scriver 1995" TYPE="BOOK_SECTION">
<AU>Scriver CR, Kaufman S, Woo SLC</AU>
<TI>The hyperphenylalaninaemias</TI>
<SO>The Metabolic and Molecular Bases of Inherited Disease</SO>
<YR>1995</YR>
<PG>1015-76</PG>
<EN>7th</EN>
<ED>Scriver CR, Beaudet AL, Sly WS, Valle D</ED>
<PB>McGraw-Hil</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-1994" MODIFIED="2008-11-07 11:26:47 +0000" MODIFIED_BY="Tracey Remmington" NAME="Smith 1994" TYPE="JOURNAL_ARTICLE">
<AU>Smith I</AU>
<TI>Treatment of phenylketonuria hydroxylase deficiency</TI>
<SO>Acta Paediatrica Supplement</SO>
<YR>1994</YR>
<VL>407</VL>
<PG>60-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2009-08-10 09:27:38 +0100" MODIFIED_BY="Nikki Jahnke"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-09-21 11:54:47 +0100" MODIFIED_BY="Nikki Jahnke">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-09-21 11:54:47 +0100" MODIFIED_BY="Nikki Jahnke" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-09-21 11:39:07 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Clarke-1987">
<CHAR_METHODS MODIFIED="2009-09-21 11:39:07 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Randomised triple-blind cross-over controlled study.<BR/>Duration 10 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>9 participants with PKU (3 males, 6 females, mean age 14.4 years). Low phenylalanine diet commenced early infancy. On relaxed diet prior to study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>All participants returned to a low-phenylalanine diet for the duration of the study. Participants ingested 3 to 4 capsules per day, each containing 500 mg L-phe during the treatment phase or 500 mg L-alanine during the control phase.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Blood phenylalanine levels.<BR/>The following neuropsychological assessments were carried out at baseline and after the first and second phase: WISC-R, Rosner's auditory analysis test; Raven's coloured progressive matrices; memory for designs; target test; wide range achievement test (arithmetic subtest); finger agnosia; simple reaction time test; choice reaction time test; grooved pegboard test; trail making tests; underlining test; verbal fluency; Stroop colour word interference test.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-07 11:18:35 +0000" MODIFIED_BY="Tracey Remmington">
<P>2 participants had continued on a phenylalanine-restricted diet prior to commencing the study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Griffiths-1998">
<CHAR_METHODS>
<P>Randomised, triple-blind, cross-over study. The study was described as being triple-blind as neither the children, their parents nor the researchers knew which intervention the children received.<BR/>Duration 6 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>16 participants with PKU (10 males, 6 females, mean age 12.6 years). All diagnosed by neonatal period and were commenced on a low-phenylalanine diet within 3 weeks of birth. Diet continued from diagnosis until study entry.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Continuation of the low phenylalanine diet in addition to a phenylalanine-free amino acid supplement for 3 months followed by a low phenylalanine diet plus an amino acid supplement containing phenylalanine for 3 months, or vice versa.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Blood phenylalanine levels measured at baseline and at the end of the first and second 3-month period. The following neuropsychological tests were carried out at the same time points: matching familiar figures; Rey verbal learning; digits forwards; paired-associate learning; Corsi block-tapping; Rey-Davis manual labyrinth; Purdue pegboard and hole-type steadiness tester.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Holtzman-1975">
<CHAR_METHODS>
<P>Randomised, controlled parallel study.<BR/>Duration 2 years.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>10 participants diagnosed with PKU in the neonatal period and commenced on a low-phenylalanine diet by 1 month of age, were randomised to either continue on the low-phenylalanine diet or to terminate the diet at 4 years of age. 5 participants were randomised to each group and the number of males and females in each group was the same (3 males, 2 females).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>The diet continuation group was continued on a low-phenylalanine diet. Those in the termination group gradually relaxed the diet following a standard protocol until the diet was unrestricted.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Blood phenylalanine levels were measured at the start of the trial, then at 2, 4, 6 and 8 weeks after the initial time point, and again 6 months, 1 year and 2 years later. Phenylalanine intake was assessed from diet diaries carried out at the same time points as the blood phenylalanine levels. The following physical examinations were carried out when the children were 4, 4.5, 5, 5.5 and 6 years of age: weight gain; height; and head circumference. Neuropsychological examinations were also carried out at these time points and included the following: Stanford Binet intelligence test; the vocabulary; similarities; animal house and the geometric designs subtests of the Wechsler preschool and primary scale of intelligence, auditory and visual sequential memory and auditory reception subtests of the Illinois test of psycholinguistic abilities. A behaviour rating of each child's performance during the test was also obtained.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-09-21 11:30:12 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-US_x002f_PKU-Collaborative">
<CHAR_METHODS MODIFIED="2009-09-21 11:30:12 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Randomised controlled parallel study.<BR/>Duration 12 years, but in some participants, outcomes were assessed into adulthood.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>216 infants diagnosed with PKU. Diet was initiated within 121 days after diagnosis. A relatively high proportion of participants was excluded or withdrew from the study following randomisation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>At diagnosis participants were randomised to follow either a low-phenylalanine diet or a moderate-phenylalanine diet until they were 6 years old. At this point they were further randomised to either continue with their diet or terminate dietary restrictions. Participants were then monitored until at least their 12th birthday.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Blood phenylalanine level.<BR/>Growth and nutritional indices.<BR/>Nutritional intake.<BR/>IQ and neuropsychological performance.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data was combined in several reports of the study therefore it was not possible to analyse the difference between treatment and control group. The trialists have been contacted for further details.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>EEG: electroencephalography<BR/>PKU: phenylketonuria</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-09-07 16:52:45 +0100" MODIFIED_BY="Nikki Jahnke" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bentovim-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unclear if randomised and dietary treatment not initiated soon after birth in all participants.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-10 09:23:02 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Cleary-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-10 09:23:02 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Trial of a specific supplement.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Epstein-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Frankenburg-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-10 09:25:24 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Kakanoglu-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-10 09:25:24 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Participants not eligible - paper states 'participants previously untreated'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Koff-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-10 09:24:32 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Koletzko-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-10 09:24:32 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Trial of a fatty acid supplement.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Krause-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-10 09:24:53 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Levy-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-10 09:24:53 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Trial of a specific supplement.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-07 16:52:45 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Lou-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-07 16:52:45 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Trial of an additional supplement.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-10 09:23:28 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Pietz-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-10 09:23:28 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Trial of tyrosine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Realmuto-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Introduced phenylalanine for one day only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rey-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Robertson-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Participants previously untreated.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-07 16:52:20 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Schindeler-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-07 16:52:20 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Trial of an additional supplement.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schmidt-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schmidt-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-10 09:23:14 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Smith-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-10 09:23:14 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Trial of tyrosine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-09-07 16:51:51 +0100" MODIFIED_BY="Nikki Jahnke" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-09-21 11:54:47 +0100" MODIFIED_BY="Nikki Jahnke">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-09-21 11:30:59 +0100" MODIFIED_BY="Nikki Jahnke" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-21 11:25:25 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Clarke-1987">
<DESCRIPTION>
<P>Method of randomisation not given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-21 11:25:10 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Griffiths-1998">
<DESCRIPTION>
<P>Method of randomisation not given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-21 11:24:55 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Holtzman-1975">
<DESCRIPTION>
<P>Participants randomly allocated, method not given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-21 11:30:59 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-US_x002f_PKU-Collaborative">
<DESCRIPTION>
<P>Treatment groups "randomly formed" using table of random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-09-21 11:32:04 +0100" MODIFIED_BY="Nikki Jahnke" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-21 11:25:32 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Clarke-1987">
<DESCRIPTION>
<P>Not discussed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-21 10:11:33 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Griffiths-1998">
<DESCRIPTION>
<P>Usual formula and experimental product prepared and coded by pharmaceutical company. Key to the code kept by a senior member of the hospital medical staff.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-21 11:24:38 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Holtzman-1975">
<DESCRIPTION>
<P>Not discussed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-21 11:32:04 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-US_x002f_PKU-Collaborative">
<DESCRIPTION>
<P>Allocation schedule produced by project staff in telephone contact with local clinic staff at participating clinics.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-09-21 11:44:42 +0100" MODIFIED_BY="Nikki Jahnke" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Participants</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Clinicians</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.03" NO="3">
<NAME>Outcome assessors</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-09-21 11:39:16 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Clarke-1987">
<DESCRIPTION>
<P>Triple-blinded. Participants continued on their usual diet but with the phenylalanine content of the diet manipulated by using additional supplements.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-09-21 11:39:28 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Clarke-1987">
<DESCRIPTION>
<P>Triple-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2009-09-21 11:39:29 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Clarke-1987">
<DESCRIPTION>
<P>Triple-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-09-21 09:59:27 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Griffiths-1998">
<DESCRIPTION>
<P>Triple-blinded, neither the children, their parents nor the researchers knew which intervention the children received. Participants continued on their usual diet but with the phenylalanine content of the diet manipulated by using additional supplements.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-09-21 11:39:46 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Griffiths-1998">
<DESCRIPTION>
<P>Triple-blinded, neither the children, their parents nor the researchers knew which intervention the children received.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2009-09-21 11:39:47 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Griffiths-1998">
<DESCRIPTION>
<P>Triple-blinded, neither the children, their parents nor the researchers knew which intervention the children received.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-09-21 11:41:42 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-Holtzman-1975">
<DESCRIPTION>
<P>Parents blinded as to which group child was in until time that restricted diet ceased, at which point they knew treatment group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-09-21 11:41:51 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-Holtzman-1975">
<DESCRIPTION>
<P>Not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2009-09-21 11:40:08 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Holtzman-1975">
<DESCRIPTION>
<P>Psychological examiner was blinded to diagnosis of PKU.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-09-21 11:44:41 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-US_x002f_PKU-Collaborative">
<DESCRIPTION>
<P>Not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-09-21 11:44:42 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-US_x002f_PKU-Collaborative">
<DESCRIPTION>
<P>Not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2009-09-21 11:42:01 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-US_x002f_PKU-Collaborative">
<DESCRIPTION>
<P>Laboratory analysis at local clinics checked by two reference laboratories. EEGs read at local clinic and Project centre, discrepancies resolved by 'blind reading' by independent third encelphalographer.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2009-09-21 11:54:47 +0100" MODIFIED_BY="Nikki Jahnke" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-07 11:22:44 +0000" MODIFIED_BY="Tracey Remmington" RESULT="YES" STUDY_ID="STD-Clarke-1987">
<DESCRIPTION>
<P>Intention-to-treat analysis was employed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-07 11:23:00 +0000" MODIFIED_BY="Tracey Remmington" RESULT="YES" STUDY_ID="STD-Griffiths-1998">
<DESCRIPTION>
<P>An intention-to-treat analysis was employed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-09-21 11:54:38 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Holtzman-1975">
<DESCRIPTION>
<P>Data on some of the participants were missing at several of the intermediate time points and at the end of the study, reasons for drop outs given (<LINK REF="STD-Holtzman-1975" TYPE="STUDY">Holtzman 1975</LINK>).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-09-21 11:54:47 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-US_x002f_PKU-Collaborative">
<DESCRIPTION>
<P>A relatively high proportion of participants were lost to follow up (reasons given) and some participants swapped groups after randomisation (<LINK REF="STD-US_x002f_PKU-Collaborative" TYPE="STUDY">US/PKU Collaborative</LINK>).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-11-07 11:25:44 +0000" MODIFIED_BY="Tracey Remmington">
<COMPARISON ID="CMP-001" MODIFIED="2008-11-07 11:25:44 +0000" MODIFIED_BY="Tracey Remmington" NO="1">
<NAME>PKU participants started on diet at diagnosis: Diet continuation versus discontinuation/relaxation later</NAME>
<CONT_OUTCOME CHI2="15.310294643275284" CI_END="-650.6357026324204" CI_START="-847.5609812795044" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-749.0983419559624" ESTIMABLE="YES" I2="67.34223529658756" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.009115627157003203" P_Q="0.7507177287059635" P_Z="2.782889905984704E-50" Q="1.2095378555025302" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="72" TOTAL_2="79" UNITS="" WEIGHT="400.0" Z="14.911298145156609">
<NAME>Blood phenylalanine level (micromol/l)</NAME>
<GROUP_LABEL_1>Low-phe diet</GROUP_LABEL_1>
<GROUP_LABEL_2>High-phe diet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low-phe</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours High-phe</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="13.781194007745835" CI_END="-527.8919372842057" CI_START="-869.4412275376245" DF="1" EFFECT_SIZE="-698.6665824109151" ESTIMABLE="YES" I2="92.74373469063752" ID="CMP-001.01.01" NO="1" P_CHI2="2.0538448563645062E-4" P_Z="1.070195579967268E-15" STUDIES="2" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0" Z="8.018528381136768">
<NAME>Blood phenylalanine level (0 to 3 months)</NAME>
<CONT_DATA CI_END="-306.5906310403762" CI_START="-704.4093689596239" EFFECT_SIZE="-505.5" ESTIMABLE="YES" MEAN_1="676.0" MEAN_2="1181.5" ORDER="47618" SD_1="316.1" SD_2="254.7" SE="101.48623675159111" STUDY_ID="STD-Griffiths-1998" TOTAL_1="16" TOTAL_2="16" WEIGHT="73.71167904043074"/>
<CONT_DATA CI_END="-907.2250531393329" CI_START="-1573.3749468606675" EFFECT_SIZE="-1240.3000000000002" ESTIMABLE="YES" MEAN_1="774.4" MEAN_2="2014.7" ORDER="47619" SD_1="205.7" SD_2="302.5" SE="169.93932005277648" STUDY_ID="STD-Holtzman-1975" TOTAL_1="4" TOTAL_2="5" WEIGHT="26.28832095956927"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-480.86546900573757" CI_START="-1261.5345309942622" DF="0" EFFECT_SIZE="-871.1999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" NO="2" P_CHI2="1.0" P_Z="1.2170795381421677E-5" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="4.374505681016457">
<NAME>Blood phenylalanine level (4 to 6 months)</NAME>
<CONT_DATA CI_END="-480.86546900573757" CI_START="-1261.5345309942622" EFFECT_SIZE="-871.1999999999999" ESTIMABLE="YES" MEAN_1="895.4" MEAN_2="1766.6" ORDER="47620" SD_1="357.0" SD_2="266.2" SE="199.15393041564607" STUDY_ID="STD-Holtzman-1975" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.3781632559555124E-31" CI_END="-456.5828648648407" CI_START="-1370.4171351351592" DF="0" EFFECT_SIZE="-913.5" ESTIMABLE="YES" I2="100.0" ID="CMP-001.01.03" NO="3" P_CHI2="0.0" P_Z="8.910390870781703E-5" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="3.9184941036359224">
<NAME>Blood phenylalanine level (7 to 12 months)</NAME>
<CONT_DATA CI_END="-456.58286486484064" CI_START="-1370.4171351351592" EFFECT_SIZE="-913.4999999999999" ESTIMABLE="YES" MEAN_1="913.6" MEAN_2="1827.1" ORDER="47621" SD_1="484.0" SD_2="193.6" SE="233.12527104541883" STUDY_ID="STD-Holtzman-1975" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.3195627800269185" CI_END="-619.6692601504016" CI_START="-883.4100024336213" DF="1" EFFECT_SIZE="-751.5396312920114" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.04" NO="4" P_CHI2="0.5718706430080138" P_Z="5.718788813993048E-29" STUDIES="2" TAU2="0.0" TOTAL_1="42" TOTAL_2="48" WEIGHT="100.0" Z="11.169989115334124">
<NAME>Blood phenylalanine level (&gt;12 months)</NAME>
<CONT_DATA CI_END="-132.68569427550295" CI_START="-1101.514305724497" EFFECT_SIZE="-617.1" ESTIMABLE="YES" MEAN_1="1010.4" MEAN_2="1627.5" ORDER="47622" SD_1="441.7" SD_2="248.1" SE="247.1546975074518" STUDY_ID="STD-Holtzman-1975" TOTAL_1="4" TOTAL_2="5" WEIGHT="7.410722250680976"/>
<CONT_DATA CI_END="-625.2538371325278" CI_START="-899.3461628674723" EFFECT_SIZE="-762.3000000000001" ESTIMABLE="YES" MEAN_1="792.6" MEAN_2="1554.9" ORDER="47623" SD_1="296.5" SD_2="332.8" SE="69.92279651487218" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="38" TOTAL_2="43" WEIGHT="92.58927774931902"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.13810986011600285" CI_END="0.014089832495829374" CI_START="-0.3804494367264676" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.1831798021153191" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2008-11-07 11:25:39 +0000" MODIFIED_BY="Tracey Remmington" NO="2" P_CHI2="0.9332754261519555" P_Q="0.9332754261519555" P_Z="0.06876280319613813" Q="0.13810986011600285" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="132" TOTAL_2="132" UNITS="" WEIGHT="300.0" Z="1.8199750587509302">
<NAME>Weight</NAME>
<GROUP_LABEL_1>Low-phe diet</GROUP_LABEL_1>
<GROUP_LABEL_2>High-phe diet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High-phe</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low-phe</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0724151242960408" CI_START="-0.47241512429604116" DF="0" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="1.0" P_Z="0.15016359354507047" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0" Z="1.438953868369004">
<NAME>Weight (0 to 3 month)</NAME>
<CONT_DATA CI_END="0.0724151242960408" CI_START="-0.47241512429604116" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="4.6" MEAN_2="4.8" ORDER="47624" SD_1="0.6" SD_2="0.7" SE="0.13898986228564233" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.15579984446079942" CI_START="-0.5557998444607998" DF="0" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" MODIFIED="2008-11-07 11:25:39 +0000" MODIFIED_BY="Tracey Remmington" NO="2" P_CHI2="1.0" P_Z="0.2705822238653123" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0" Z="1.1017227888394965">
<NAME>Weight (4 to 6 months)</NAME>
<CONT_DATA CI_END="0.15579984446079942" CI_START="-0.5557998444607998" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="7.0" ORDER="47625" SD_1="0.9" SD_2="0.8" SE="0.18153386861559873" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.38099957179246313" CI_START="-0.5809995717924624" DF="0" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.03" MODIFIED="2008-11-07 11:25:39 +0000" MODIFIED_BY="Tracey Remmington" NO="3" P_CHI2="1.0" P_Z="0.683657476923542" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0" Z="0.4074772826171484">
<NAME>Weight (7 to 12 months)</NAME>
<CONT_DATA CI_END="0.38099957179246313" CI_START="-0.5809995717924624" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="9.4" MEAN_2="9.5" ORDER="47626" SD_1="1.2" SD_2="1.1" SE="0.2454124543035107" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.595314750150903" CI_START="0.4046852498490967" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2008-11-07 11:25:44 +0000" MODIFIED_BY="Tracey Remmington" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.03296020328512377" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="53" TOTAL_2="62" UNITS="" WEIGHT="100.0" Z="2.132567725067899">
<NAME>Intelligence Quotient (IQ)</NAME>
<GROUP_LABEL_1>Low-phe diet</GROUP_LABEL_1>
<GROUP_LABEL_2>High-phe diet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High-phe</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low-phe</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.595314750150903" CI_START="0.4046852498490967" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" MODIFIED="2008-11-07 11:25:44 +0000" MODIFIED_BY="Tracey Remmington" NO="1" P_CHI2="1.0" P_Z="0.03296020328512377" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="62" WEIGHT="100.0" Z="2.132567725067899">
<NAME>IQ (&gt; 12 months)</NAME>
<CONT_DATA CI_END="9.595314750150903" CI_START="0.4046852498490967" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="102.0" MEAN_2="97.0" ORDER="47627" SD_1="12.3" SD_2="12.8" SE="2.3445914243313446" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="53" TOTAL_2="62" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.7797982461923914" CI_END="0.37412165945417764" CI_START="-8.293815732111922" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.959847036328872" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="0.6771253707547558" P_Q="0.6771253707547558" P_Z="0.07332960181831912" Q="0.7797982461923914" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="132" TOTAL_2="132" UNITS="" WEIGHT="300.0" Z="1.7907737965536912">
<NAME>Calorie intake (kcal/kg)</NAME>
<GROUP_LABEL_1>Low-phe diet</GROUP_LABEL_1>
<GROUP_LABEL_2>High-phe diet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High-phe</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low-phe</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.06353931053401" CI_START="-11.06353931053401" DF="0" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" NO="1" P_CHI2="1.0" P_Z="0.8455816884858423" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0" Z="0.19475891374404053">
<NAME>Calorie intake (0 to 3 months)</NAME>
<CONT_DATA CI_END="9.06353931053401" CI_START="-11.06353931053401" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="122.0" MEAN_2="123.0" ORDER="47628" SD_1="22.0" SD_2="26.0" SE="5.134553180524705" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.115996889215991" CI_START="-10.11599688921599" DF="0" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" NO="2" P_CHI2="1.0" P_Z="0.4086384264467885" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0" Z="0.8262920916296217">
<NAME>Calorie intake (4 to 6 months)</NAME>
<CONT_DATA CI_END="4.115996889215991" CI_START="-10.11599688921599" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="95.0" MEAN_2="98.0" ORDER="47629" SD_1="18.0" SD_2="16.0" SE="3.630677372311974" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.507177030781004" CI_START="-12.507177030781005" DF="0" EFFECT_SIZE="-6.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.03" NO="3" P_CHI2="1.0" P_Z="0.0707307757423343" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0" Z="1.8072020864981588">
<NAME>Calorie intake (7 to 12 months)</NAME>
<CONT_DATA CI_END="0.507177030781004" CI_START="-12.507177030781005" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="85.0" MEAN_2="91.0" ORDER="47630" SD_1="14.0" SD_2="17.0" SE="3.3200492876954812" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.211053973467007" CI_END="0.05749786964381501" CI_START="-0.2311377296325797" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.08681992999438234" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="0.8998501902541561" P_Q="0.8998501902541561" P_Z="0.23836163937843813" Q="0.211053973467007" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="132" TOTAL_2="132" UNITS="" WEIGHT="300.0" Z="1.1790918123466179">
<NAME>Protein intake (g/kg)</NAME>
<GROUP_LABEL_1>Low-phe diet</GROUP_LABEL_1>
<GROUP_LABEL_2>High-phe diet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low-phe</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours High-phe</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.39752188234384056" CI_START="-0.39752188234384056" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="99.99999999999999" Z="0.0">
<NAME>Protein intake (0 to 3 months)</NAME>
<CONT_DATA CI_END="0.39752188234384056" CI_START="-0.39752188234384056" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="4.2" ORDER="47631" SD_1="0.9" SD_2="1.0" SE="0.20282101379384643" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="44" TOTAL_2="44" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.13077388976222312" CI_START="-0.3307738897622233" DF="0" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.02" NO="2" P_CHI2="1.0" P_Z="0.39571406666633746" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0" Z="0.8493005801304019">
<NAME>Protein intake (4 to 6 months)</NAME>
<CONT_DATA CI_END="0.1307738897622231" CI_START="-0.33077388976222327" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="3.1" ORDER="47632" SD_1="0.5" SD_2="0.6" SE="0.11774394406353289" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.108932862767568" CI_START="-0.30893286276756815" DF="0" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.03" NO="3" P_CHI2="1.0" P_Z="0.34820169066078" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.00000000000001" Z="0.9380831519646867">
<NAME>Protein intake (7 to 12 months)</NAME>
<CONT_DATA CI_END="0.108932862767568" CI_START="-0.30893286276756815" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="2.6" ORDER="47633" SD_1="0.5" SD_2="0.5" SE="0.10660035817780522" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>PKU participants on strict diet from diagnosis, later relaxed: Diet re-establishment versus continuation</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-360.73368615144494" CI_START="-867.266313848555" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-614.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="2.0182249297131765E-6" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="9" TOTAL_2="9" UNITS="" WEIGHT="100.0" Z="4.751590798716317">
<NAME>Blood phenylalanine level (micromol/l)</NAME>
<GROUP_LABEL_1>Low-phe diet</GROUP_LABEL_1>
<GROUP_LABEL_2>High-phe diet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low-phe</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours High-phe</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-360.73368615144494" CI_START="-867.266313848555" DF="0" EFFECT_SIZE="-614.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" NO="1" P_CHI2="1.0" P_Z="2.0182249297131765E-6" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="100.0" Z="4.751590798716317">
<NAME>Blood phenylalanine level (0 to 3 months)</NAME>
<CONT_DATA CI_END="-360.73368615144494" CI_START="-867.266313848555" EFFECT_SIZE="-614.0" ESTIMABLE="YES" MEAN_1="713.0" MEAN_2="1327.0" ORDER="47634" SD_1="266.0" SD_2="282.0" SE="129.21988151123563" STUDY_ID="STD-Clarke-1987" TOTAL_1="9" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>PKU participants at diagnosis: Low-phenylalanine diet versus moderate phenylalanine diet</NAME>
<CONT_OUTCOME CHI2="6.647152818990842" CI_END="-76.5180180294487" CI_START="-135.12385079511563" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-105.82093441228217" ESTIMABLE="YES" I2="24.77982474368492" I2_Q="24.77982474368492" ID="CMP-003.01" NO="1" P_CHI2="0.24823212101147774" P_Q="0.24823212101147774" P_Z="1.4627932149225205E-12" Q="6.647152818990842" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="387" TOTAL_2="391" UNITS="" WEIGHT="600.0" Z="7.077971951622963">
<NAME>Blood phenylalanine level (micromol/l)</NAME>
<GROUP_LABEL_1>Low-phe diet</GROUP_LABEL_1>
<GROUP_LABEL_2>High-phe diet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low-phe</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours High-phe</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-69.15584892911266" CI_START="-185.04415107088738" DF="0" EFFECT_SIZE="-127.10000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.01" NO="1" P_CHI2="1.0" P_Z="1.7144338854379798E-5" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="66" WEIGHT="100.0" Z="4.299164244037065">
<NAME>Blood phenylalanine level (0 to 3 months)</NAME>
<CONT_DATA CI_END="-69.15584892911266" CI_START="-185.04415107088738" EFFECT_SIZE="-127.10000000000002" ESTIMABLE="YES" MEAN_1="326.7" MEAN_2="453.8" ORDER="47635" SD_1="181.5" SD_2="157.3" SE="29.563885626441824" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="66" TOTAL_2="66" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-97.42186819930046" CI_START="-217.17813180069956" DF="0" EFFECT_SIZE="-157.3" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.02" NO="2" P_CHI2="1.0" P_Z="2.6211599454188466E-7" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="66" WEIGHT="100.0" Z="5.148830223934086">
<NAME>Blood phenylalanine levels (7 to 12 months)</NAME>
<CONT_DATA CI_END="-97.42186819930046" CI_START="-217.17813180069956" EFFECT_SIZE="-157.3" ESTIMABLE="YES" MEAN_1="344.9" MEAN_2="502.2" ORDER="47636" SD_1="175.5" SD_2="175.5" SE="30.55062862022497" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="66" TOTAL_2="66" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-11.38317505488537" CI_START="-158.0168249451146" DF="0" EFFECT_SIZE="-84.69999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.03" NO="3" P_CHI2="1.0" P_Z="0.023557629013165587" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="66" WEIGHT="100.0" Z="2.2642681214689504">
<NAME>Blood phenylalanine level (at 2 years)</NAME>
<CONT_DATA CI_END="-11.38317505488537" CI_START="-158.0168249451146" EFFECT_SIZE="-84.69999999999999" ESTIMABLE="YES" MEAN_1="453.8" MEAN_2="538.5" ORDER="47637" SD_1="248.1" SD_2="175.5" SE="37.40723070598663" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="66" TOTAL_2="66" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="28.59259310571896" CI_START="-125.39259310571892" DF="0" EFFECT_SIZE="-48.39999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.04" NO="4" P_CHI2="1.0" P_Z="0.21791329317570263" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="65" WEIGHT="100.0" Z="1.2320958812425333">
<NAME>Blood phenylalanine level (at 3 years)</NAME>
<CONT_DATA CI_END="28.59259310571896" CI_START="-125.39259310571892" EFFECT_SIZE="-48.39999999999998" ESTIMABLE="YES" MEAN_1="550.6" MEAN_2="599.0" ORDER="47638" SD_1="242.0" SD_2="199.7" SE="39.28265708606214" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="63" TOTAL_2="65" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="17.089981635756274" CI_START="-174.48998163575612" DF="0" EFFECT_SIZE="-78.69999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.05" NO="5" P_CHI2="1.0" P_Z="0.10733566372749356" STUDIES="1" TAU2="0.0" TOTAL_1="64" TOTAL_2="63" WEIGHT="100.0" Z="1.6102849478543426">
<NAME>Blood phenylalanine level (at 4 years)</NAME>
<CONT_DATA CI_END="17.089981635756274" CI_START="-174.48998163575612" EFFECT_SIZE="-78.69999999999993" ESTIMABLE="YES" MEAN_1="617.1" MEAN_2="695.8" ORDER="47639" SD_1="284.4" SD_2="266.2" SE="48.87333766912829" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="64" TOTAL_2="63" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="17.150700391009536" CI_START="-162.35070039100958" DF="0" EFFECT_SIZE="-72.60000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.06" NO="6" P_CHI2="1.0" P_Z="0.11286884064938651" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="65" WEIGHT="100.0" Z="1.5854292463199728">
<NAME>Blood phenylalanine level (at 5 years)</NAME>
<CONT_DATA CI_END="17.150700391009536" CI_START="-162.35070039100958" EFFECT_SIZE="-72.60000000000002" ESTIMABLE="YES" MEAN_1="641.3" MEAN_2="713.9" ORDER="47640" SD_1="272.3" SD_2="242.0" SE="45.792015107905875" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="62" TOTAL_2="65" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.13810986011600285" CI_END="0.014089832495829346" CI_START="-0.3804494367264676" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.18317980211531912" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" NO="2" P_CHI2="0.9332754261519555" P_Q="0.9332754261519555" P_Z="0.06876280319613812" Q="0.13810986011600285" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="132" TOTAL_2="132" UNITS="" WEIGHT="300.0" Z="1.8199750587509305">
<NAME>Weight (kg)</NAME>
<GROUP_LABEL_1>Low-phe diet</GROUP_LABEL_1>
<GROUP_LABEL_2>High-phe diet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High-phe</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low-phe</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0724151242960408" CI_START="-0.47241512429604116" DF="0" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.01" NO="1" P_CHI2="1.0" P_Z="0.15016359354507047" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0" Z="1.438953868369004">
<NAME>Weight (0 to 3 months)</NAME>
<CONT_DATA CI_END="0.0724151242960408" CI_START="-0.47241512429604116" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="4.6" MEAN_2="4.8" ORDER="47641" SD_1="0.6" SD_2="0.7" SE="0.13898986228564233" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.15579984446079942" CI_START="-0.5557998444607998" DF="0" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.02" NO="2" P_CHI2="1.0" P_Z="0.2705822238653123" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0" Z="1.1017227888394965">
<NAME>Weight (4 to 6 months)</NAME>
<CONT_DATA CI_END="0.15579984446079942" CI_START="-0.5557998444607998" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="7.0" ORDER="47642" SD_1="0.9" SD_2="0.8" SE="0.18153386861559873" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.38099957179246313" CI_START="-0.5809995717924624" DF="0" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.03" NO="3" P_CHI2="1.0" P_Z="0.683657476923542" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0" Z="0.4074772826171484">
<NAME>Weight (7 to 12 months)</NAME>
<CONT_DATA CI_END="0.38099957179246313" CI_START="-0.5809995717924624" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="9.4" MEAN_2="9.5" ORDER="47643" SD_1="1.2" SD_2="1.1" SE="0.2454124543035107" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.06145314199740085" CI_END="6.4128784919144906" CI_START="-1.4771333609364916" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="2.4678725654889995" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" NO="3" P_CHI2="0.8042137616611307" P_Q="0.8042137616611307" P_Z="0.22016397033532786" Q="0.06145314199740085" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="124" TOTAL_2="119" UNITS="" WEIGHT="200.0" Z="1.2260922890870238">
<NAME>Intelligence Quotient (IQ)</NAME>
<GROUP_LABEL_1>Low-phe diet</GROUP_LABEL_1>
<GROUP_LABEL_2>High-phe diet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High-phe</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low-phe</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.2775550592168742E-32" CI_END="8.767450420171244" CI_START="-2.7674504201712433" DF="0" EFFECT_SIZE="3.0000000000000004" ESTIMABLE="YES" I2="100.0" ID="CMP-003.03.01" NO="1" P_CHI2="0.0" P_Z="0.30796762125524413" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="53" WEIGHT="100.0" Z="1.0194958821068776">
<NAME>IQ at 4 years</NAME>
<CONT_DATA CI_END="8.767450420171244" CI_START="-2.7674504201712438" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="94.0" MEAN_2="91.0" ORDER="47644" SD_1="16.0" SD_2="15.0" SE="2.9426308165171178" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="58" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.408039249805164" CI_START="-3.4080392498051637" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.02" NO="2" P_CHI2="1.0" P_Z="0.46855419234643303" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="66" WEIGHT="100.0" Z="0.7248334910330638">
<NAME>IQ at 6 years</NAME>
<CONT_DATA CI_END="7.408039249805164" CI_START="-3.4080392498051637" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="99.0" MEAN_2="97.0" ORDER="47645" SD_1="16.0" SD_2="15.7" SE="2.7592544008273046" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="66" TOTAL_2="66" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.7797982461923914" CI_END="0.37412165945417764" CI_START="-8.293815732111922" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.959847036328872" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.04" NO="4" P_CHI2="0.6771253707547558" P_Q="0.6771253707547558" P_Z="0.07332960181831912" Q="0.7797982461923914" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="132" TOTAL_2="132" UNITS="" WEIGHT="300.0" Z="1.7907737965536912">
<NAME>Calorie intake (kcal/kg)</NAME>
<GROUP_LABEL_1>Low-phe diet</GROUP_LABEL_1>
<GROUP_LABEL_2>High-phe diet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High-phe</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low-phe</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.06353931053401" CI_START="-11.06353931053401" DF="0" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.01" NO="1" P_CHI2="1.0" P_Z="0.8455816884858423" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0" Z="0.19475891374404053">
<NAME>Calorie intake (0 to 3 months)</NAME>
<CONT_DATA CI_END="9.06353931053401" CI_START="-11.06353931053401" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="122.0" MEAN_2="123.0" ORDER="47646" SD_1="22.0" SD_2="26.0" SE="5.134553180524705" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.115996889215991" CI_START="-10.11599688921599" DF="0" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.02" NO="2" P_CHI2="1.0" P_Z="0.4086384264467885" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0" Z="0.8262920916296217">
<NAME>Calorie intake (4 to 6 months)</NAME>
<CONT_DATA CI_END="4.115996889215991" CI_START="-10.11599688921599" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="95.0" MEAN_2="98.0" ORDER="47647" SD_1="18.0" SD_2="16.0" SE="3.630677372311974" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.507177030781004" CI_START="-12.507177030781005" DF="0" EFFECT_SIZE="-6.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.03" NO="3" P_CHI2="1.0" P_Z="0.0707307757423343" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0" Z="1.8072020864981588">
<NAME>Calorie intake (7 to 12 months)</NAME>
<CONT_DATA CI_END="0.507177030781004" CI_START="-12.507177030781005" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="85.0" MEAN_2="91.0" ORDER="47648" SD_1="14.0" SD_2="17.0" SE="3.3200492876954812" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.211053973467007" CI_END="0.05749786964381501" CI_START="-0.2311377296325797" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.08681992999438234" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.05" NO="5" P_CHI2="0.8998501902541561" P_Q="0.8998501902541561" P_Z="0.23836163937843813" Q="0.211053973467007" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="132" TOTAL_2="132" UNITS="" WEIGHT="300.0" Z="1.1790918123466179">
<NAME>Protein intake (g/kg)</NAME>
<GROUP_LABEL_1>Low-phe diet</GROUP_LABEL_1>
<GROUP_LABEL_2>High-phe diet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low-phe</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours High-phe</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.39752188234384056" CI_START="-0.39752188234384056" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.05.01" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="99.99999999999999" Z="0.0">
<NAME>Protein intake (0 to 3 months)</NAME>
<CONT_DATA CI_END="0.39752188234384056" CI_START="-0.39752188234384056" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="4.2" ORDER="47649" SD_1="0.9" SD_2="1.0" SE="0.20282101379384643" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="44" TOTAL_2="44" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.13077388976222312" CI_START="-0.3307738897622233" DF="0" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" I2="0.0" ID="CMP-003.05.02" NO="2" P_CHI2="1.0" P_Z="0.39571406666633746" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0" Z="0.8493005801304019">
<NAME>Protein intake (4 to 6 months)</NAME>
<CONT_DATA CI_END="0.1307738897622231" CI_START="-0.33077388976222327" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="3.1" ORDER="47650" SD_1="0.5" SD_2="0.6" SE="0.11774394406353289" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.108932862767568" CI_START="-0.30893286276756815" DF="0" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" I2="0.0" ID="CMP-003.05.03" NO="3" P_CHI2="1.0" P_Z="0.34820169066078" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.00000000000001" Z="0.9380831519646867">
<NAME>Protein intake (7 to 12 months)</NAME>
<CONT_DATA CI_END="0.108932862767568" CI_START="-0.30893286276756815" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="2.6" ORDER="47651" SD_1="0.5" SD_2="0.5" SE="0.10660035817780522" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="220.118774313254" CI_END="-72.60039224370773" CI_START="-75.9189340389431" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="MD" EFFECT_SIZE="-74.25966314132542" ESTIMABLE="YES" I2="95.91129833060401" I2_Q="95.91129833060401" ID="CMP-003.06" NO="6" P_CHI2="9.992007221626409E-16" P_Q="9.992007221626409E-16" P_Z="0.0" Q="220.118774313254" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="676" TOTAL_2="644" UNITS="" WEIGHT="1000.0" Z="87.71699996067161">
<NAME>Phenylalanine intake (mg/day)</NAME>
<GROUP_LABEL_1>Low-phe diet</GROUP_LABEL_1>
<GROUP_LABEL_2>High-phe diet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low-phe</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high-phe</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-60.464095674333926" CI_START="-67.53590432566608" DF="0" EFFECT_SIZE="-64.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.01" NO="1" P_CHI2="1.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="73" WEIGHT="100.0" Z="35.47542112495767">
<NAME>At 15 months of age</NAME>
<CONT_DATA CI_END="-60.464095674333926" CI_START="-67.53590432566608" EFFECT_SIZE="-64.0" ESTIMABLE="YES" MEAN_1="285.0" MEAN_2="349.0" ORDER="47652" SD_1="10.0" SD_2="12.0" SE="1.804065969352925" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="78" TOTAL_2="73" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-59.192028897137625" CI_START="-68.80797110286238" DF="0" EFFECT_SIZE="-64.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.02" NO="2" P_CHI2="1.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="67" WEIGHT="100.0" Z="26.089527646263395">
<NAME>At 21 months of age</NAME>
<CONT_DATA CI_END="-59.192028897137625" CI_START="-68.80797110286238" EFFECT_SIZE="-64.0" ESTIMABLE="YES" MEAN_1="299.0" MEAN_2="363.0" ORDER="47653" SD_1="11.0" SD_2="17.0" SE="2.4530915571852536" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="71" TOTAL_2="67" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-83.43608587162366" CI_START="-92.56391412837634" DF="0" EFFECT_SIZE="-88.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.03" NO="3" P_CHI2="1.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="68" WEIGHT="100.0" Z="37.79142766230902">
<NAME>At 27 months of age</NAME>
<CONT_DATA CI_END="-83.43608587162366" CI_START="-92.56391412837634" EFFECT_SIZE="-88.0" ESTIMABLE="YES" MEAN_1="306.0" MEAN_2="394.0" ORDER="47654" SD_1="11.0" SD_2="16.0" SE="2.3285704045461637" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="73" TOTAL_2="68" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-68.14964405660088" CI_START="-77.85035594339912" DF="0" EFFECT_SIZE="-73.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.04" NO="4" P_CHI2="1.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="69" WEIGHT="100.0" Z="29.498323945923797">
<NAME>At 33 months of age</NAME>
<CONT_DATA CI_END="-68.14964405660088" CI_START="-77.85035594339912" EFFECT_SIZE="-73.0" ESTIMABLE="YES" MEAN_1="335.0" MEAN_2="408.0" ORDER="47655" SD_1="10.0" SD_2="18.0" SE="2.474716873196704" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="70" TOTAL_2="69" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-75.0642184217645" CI_START="-84.9357815782355" DF="0" EFFECT_SIZE="-80.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.05" NO="5" P_CHI2="1.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="62" WEIGHT="100.0" Z="31.76743465606469">
<NAME>At 39 months of age</NAME>
<CONT_DATA CI_END="-75.0642184217645" CI_START="-84.9357815782355" EFFECT_SIZE="-80.0" ESTIMABLE="YES" MEAN_1="351.0" MEAN_2="431.0" ORDER="47656" SD_1="11.0" SD_2="17.0" SE="2.518302181656562" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="72" TOTAL_2="62" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.485902157103025E-30" CI_END="-52.05414565627183" CI_START="-63.945854343728186" DF="0" EFFECT_SIZE="-58.00000000000001" ESTIMABLE="YES" I2="100.0" ID="CMP-003.06.06" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="68" WEIGHT="100.0" Z="19.118852318209434">
<NAME>At 45 months of age</NAME>
<CONT_DATA CI_END="-52.05414565627182" CI_START="-63.94585434372818" EFFECT_SIZE="-58.0" ESTIMABLE="YES" MEAN_1="378.0" MEAN_2="436.0" ORDER="47657" SD_1="18.0" SD_2="18.0" SE="3.0336548990840244" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="73" TOTAL_2="68" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-77.03363440567887" CI_START="-88.96636559432113" DF="0" EFFECT_SIZE="-83.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.07" NO="7" P_CHI2="1.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="60" WEIGHT="100.0" Z="27.265679272430575">
<NAME>At 51 months of age</NAME>
<CONT_DATA CI_END="-77.03363440567887" CI_START="-88.96636559432113" EFFECT_SIZE="-83.0" ESTIMABLE="YES" MEAN_1="366.0" MEAN_2="449.0" ORDER="47658" SD_1="13.0" SD_2="20.0" SE="3.0441200151549" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="65" TOTAL_2="60" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-62.39231217989936" CI_START="-75.60768782010064" DF="0" EFFECT_SIZE="-69.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.08" NO="8" P_CHI2="1.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="57" WEIGHT="100.0" Z="20.466692527735674">
<NAME>At 57 months of age</NAME>
<CONT_DATA CI_END="-62.39231217989936" CI_START="-75.60768782010064" EFFECT_SIZE="-69.0" ESTIMABLE="YES" MEAN_1="404.0" MEAN_2="473.0" ORDER="47659" SD_1="15.0" SD_2="21.0" SE="3.371331244972477" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="62" TOTAL_2="57" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-99.45847700411659" CI_START="-112.54152299588341" DF="0" EFFECT_SIZE="-106.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.09" NO="9" P_CHI2="1.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="60" WEIGHT="100.0" Z="31.759604375309365">
<NAME>At 63 months of age</NAME>
<CONT_DATA CI_END="-99.45847700411659" CI_START="-112.54152299588341" EFFECT_SIZE="-106.0" ESTIMABLE="YES" MEAN_1="385.0" MEAN_2="491.0" ORDER="47660" SD_1="13.0" SD_2="22.0" SE="3.337573061281796" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="55" TOTAL_2="60" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-63.8245113074795" CI_START="-90.1754886925205" DF="0" EFFECT_SIZE="-77.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.10" NO="10" P_CHI2="1.0" P_Z="2.2352335063616458E-30" STUDIES="1" TAU2="0.0" TOTAL_1="57" TOTAL_2="60" WEIGHT="100.0" Z="11.454393103100402">
<NAME>At 69 months of age</NAME>
<CONT_DATA CI_END="-63.8245113074795" CI_START="-90.1754886925205" EFFECT_SIZE="-77.0" ESTIMABLE="YES" MEAN_1="453.0" MEAN_2="530.0" ORDER="47661" SD_1="30.0" SD_2="42.0" SE="6.722311632482573" STUDY_ID="STD-US_x002f_PKU-Collaborative" TOTAL_1="57" TOTAL_2="60" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>